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ABSTRACT
Liposomal drug delivery shows great promise for developing smart delivery
materials, especially when a cytotoxic drug needs to be administered. The
liposome membrane bilayer structure reduces toxicity through encapsulation,
circumventing side effects. Current work in this field is aimed at selectively
targeting delivery to diseased cells and controlling the release of encapsulated
drugs.
In the first project of this dissertation, we describe the synthesis of a clickable
and photocleavable lipid analog for efficient drug delivery to cells and subsequent
triggered release. This lipid analog contains a cyclooctyne moiety by which
azide-containing drug molecules or fluorophores can be attached using copperfree click chemistry and a photocleavable group for light-driven release. We have
validated conjugation of this lipid analog via click chemistry using fluorescencebased liposome derivatization studies and a liposome immobilization microplate
assay. Next, fluorescence microscopy was used to show successful delivery of
fluorescent dyes to cells and subsequent release. Finally, this lipid was applied
for liposomal delivery of camptothecin to cancer cells, which led to a dosedependent decrease in cell viability.
Metabolic labeling of biomolecules is another topic of interest described in this
dissertation. In this project, we sought to design, synthesize and study clicktagged serine analogs that could produce labeled versions of phosphatidylserine
in cells to investigate lipid production, trafficking, and to understand the role of
v

lipids in the instigation of cancer and other diseases. In studies, either
Saccharomyces cerevisiae or human cells were treated with these probes,
followed by incubation with a clickable fluorescent reagent and confocal
fluorescence microscopy to detect labeled products. To determine the labeled
lipids,

the

extracted

cell

samples

were

subjected

to

tandem

mass

spectrophotometry and a number of phospholipids were detected. Lastly, we also
showed that click labeling of PS, a lipid upregulated on the outer leaflet of cancer
cell membranes, can be utilized as a tool for delivery the delivery of liposomes
bearing partner clickable tags, which has been confirmed via a confocal
microscope. Finally, we have synthesized a number of L-serine analogs as
potential PS synthase inhibitors and worked to evaluate the efficacy of these
compounds using a PS synthase assay.
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CHAPTER ONE
INTRODUCTION TO DRUG CARRIER VESICLES AND
TECHNIQUES FOR EFFICIENT DRUG DELIVERY
1.1 Common Drug Delivery Vehicles
Modern research in drug delivery and release involves the development of
smart biotunable drug carriers, which may involve the use of targeting groups for
delivery to specific diseased sites and/or a stimulus-driven release technique that
ensures discharge of payloads in the biological system. Pharmaceutical research
has been continued in search of ideal drug carriers with selectivity for delivering
drugs to diseased cells that are often toxic to healthy tissues. Furthermore, if the
drug is unencapsulated or unconjugated to a delivery vehicle, a number of
complications such as poor localization, off-site effects, and short circulation
periods1 diminish the overall efficacy of the drug. For example, well-known drug
carriers including micelles, cyclodextrin, nanotubes, dendrimers (Figure 1.1) etc.
are insufficient to overcome many of these obstacles. The reasons for this
include the hydrophobic nature of these carriers, their ability to encapsulate only
hydrophobic molecules, short circulation periods in the blood stream and to the
lack of biotunable properties. Carbon nanotubes are highly hydrophobic
polycyclic structures that have high surface areas for attachment of drugs,
proteins, or other molecules,2 whereas micelles are only capable of hydrophobic
entrapment. Dendrimers consist of polymeric materials with a high amount of
branching resulting in large surface areas for functionalization, whereas a
1

nanoshell plasmons are spherical nanoparticles consisting of a dielectric core
that is covered by a thin metallic shell.
In 1960, a new idea for the delivery vehicle was established by Bingham who
came up with the concept of liposomes; spherical bilayer structures formed by
lipids when they are suspended in aqueous medium. Liposomes can be widely
applied to carry polar drugs in the internal aqueous environment and the
hydrophobic membrane core can be utilized to entrap nonpolar drugs. One of the
most beneficial aspects of liposomes is that the membrane bilayer structure
reduces toxicity by encapsulating the cytotoxic chemical, which is maximized
when the drug is selectively released at the location of the diseased tissue.

Figure 1.1: Common drug delivery vehicles suitable for entrapping drug
moieties.
2

Moreover, liposomes are biocompatible as they are mimics of natural lipids
and cell membranes, thus diminishing clearance by the immune system.
Liposomes including DaunoXome (danorubicin) and Myocet (doxorubicin) 3
showcase this low toxicity and are already available in the market as drug
carriers.4 Still these popular drugs are facing challenges since they are cleared
by the reticuloendothelial system (RES) in a short period of time. Incorporation of
polyethylene glycol (PEG) onto the surfaces of liposomes during the formulation
process has been used to enhance the circulation time as well as the overall
efficiency of drug delivery.
1.2 Derivatization of Liposomal Surfaces
The derivatization of lipid-based nanodrug carriers enables numerous
therapeutic applications and can be performed either before or after selfassembly. The ability to functionalize liposomes of varying composition with
different targeting groups makes these carriers beneficial as biotunable systems
compared to other candidates including micelles, albumin, nanodrugs, and lipidcoated nanoparticles. Furthermore, designing a nanodrug carrier aimed for highly
specific delivery to the surfaces of targeted cells is crucial. This results in highly
tunable biocompatible medicinal nanocarriers that have been established as
effective tools for imaging and therapeutic applications.5-8
More recent strategies for the post-conjugation of liposomal membranes
include click/bioorthogonal chemistry including the copper-catalyzed azide-alkyne
cycloaddition (CuAAC), copper-free click chemistry, the Staudinger ligation,
3

tetrazine/trans-cyclooctene

inverse

electron

demand

Diels-Alder

(IEDDA)

cycloaddition as well as enzymatic modification and the His-Tag chelation
strategy.17 Maleimide/thiol chemistry, prior to click chemistry, has been used for
derivatization of intact liposomes. An alternative method is post-modificationhere 5-10 mol% of synthetic lipids with short PEG-linked head groups with a wide
variety of functional groups such as amines, carboxylic acids, thiols or
maleimides—can be self-assembled into the bilayer. PEGs can then be grafted
on after liposome formation via the appropriate chemistry, be it amide
conjugation, hydrazine bonding, thioester formation or disulfide bond formation9
Later, click chemistry emerged as a class of high-yielding reactions that is
broadly tolerant to conditions and other functional groups that are present. 10 As a
result, click reactions also benefit from their bioorthogonal nature, meaning that
the reactive partner functional groups used for these reactions can selectively
react with one another in high yield without side products within the complex
environment of biological systems.11-13 Since its inception, the click chemistry
philosophy has been advantageous for numerous applications including
liposomal drug delivery.
1.2.1 Azide-Alkyne Cycloaddition: The azide-alkyne cycloaddition reaction, the
most prominent member of a family of reactions known as “click chemistry”,
involves a 1,3-dipolar cycloaddition reaction forming a triazole ring. This reaction
was first reported by Huisgen14 and later in 2002, modified by Sharpless and coworkers15 and Meldal and co-workers.16 This modification introduced the use of a
4

copper (I) catalyst that dramatically improved overall reaction rate and yields.
Moreover, other benefits of the copper-catalyzed azide-alkyne cycloaddition
include improved chemo- and regioselectivity, reaction scope, and water
compatibility.17 For instance, the proximity between the alkyne and azide reactive
partners caused by reporter binding increases the reaction rate and has been
used for templated synthesis of high-affinity enzyme inhibitors. Lastly, as with
other cycloadditions, the reaction rate is enhanced when the reactive groups are
polarized, and thus, it is common to include an electron withdrawing or donating
group proximal to the alkyne. Moreover, several studies have been performed to
elucidate the reaction mechanism18, 19 and optimize reaction conditions and it has
been found that the addition of a ligand that chelates copper enhances the
reaction rate and stabilizes the metal.20, 21
1.2.2 Copper-Free Azide-Alkyne Cycloaddition: Although the coppercatalyzed azide-alkyne cycloaddition is effective for in vitro biological studies, the
mandatory application of the copper catalyst can be detrimental to in vivo
studies. The need for the copper in this click reaction requires the delivery of this
catalyst to the reaction site, which is problematic since copper is toxic to living
cells.22 The strain promoted azide-alkyne cycloaddition reaction (SPAAC) (also
known as the copper-free azide-alkyne cycloaddition), reported by Bertozzi and
co-workers,23 overcomes this this obstacle. This reaction is effective in the
absence of copper catalyst due to the incorporation of the alkyne within a
strained cyclooctyne ring, which increases its intrinsic reactivity.
5

Figure 1.2: Bioorthogonal reactions that are effective for bioconjugation
both in vitro and in vivo.

A variety of cyclooctyne reagents have been developed for copper-free click
chemistry. For example, difluorocyclooctyne (DIFO, Figure 1.2) reagents led to
enhanced reactivity due to the polarization caused by the electron withdrawing
fluorine groups.24 Copper-free click reactions have proven to be invaluable for in
vivo labeling.25-27 For example, Baskin et al. demonstrated selective labeling of
biomolecules such as glycans employing a Cu-free variant of click chemistry in
living systems.28 The enhanced reactivity of DIFO was important for enhancing
6

bioorthogonal imaging of azide-tagged sugars in living organisms. Additionally,
Ning and co-workers synthesized a dibenzocyclooctyne reactant with increased
hydrophilicity.29,

30

known as ADIBO30,

Specifically, azodibenzocyclooctyne reagents, commonly
31

or DIBACO have become very popular in bioorthoganl

chemistry for their wide applications in vivo studies.

27, 32

These compounds

participate in a copper free click reaction at a faster reaction rate. Recently, near
infrared (NIR) fluorogenic probes activated by bioorthogonal chemistry have
become attractive for visualization of biomolecules in living systems.46 Here
labeled cyclooctyne species can be clicked via SPAAC onto NIR fluorogenic
azide probes and later monitored on microscopy at near IR range, where tissue
penetrance is highest and background fluorescence from the excess probe and
endogenous biomolecules is minimized at these wavelengths.
1.2.3 Staudinger Ligation: The Staudinger ligation reaction is another example
of a biorthogonal reaction suitable for in vivo labeling. This reaction emerged as a
modification to the Staudinger Reduction reaction 33 by the formation of an
azaylide intermediate as a result of an intramolecular attack of an electrophile,
commonly to an ester, attached to a phosphine reagent. While the original
reaction product contained a phosphine oxide moiety, a later modification termed
the “traceless Staudinger ligation” was designed such that the phosphine is
released, resulting in a simple amide bond linkage.34, 35 The original reaction has
been employed for aza-ylide capture using several phosphine reagents
containing different groups as shown in Figure 1.2. Since this time, the
7

mechanism of the reaction and other details have been probed in depth 36, and a
number of replications have been reported, such as fluorogenic versions 37,
including an FRET-based system38, as well as reagents with increased water
solubility39 .
1.2.4 Applications of Bioorthogonal Chemistry in Functionalization of
Membranes
The copper-catalyzed azide–alkyne cycloaddition (CuAAC) has been
effectively employed to derivatize membrane surfaces. 40,

41

This was initially

accomplished for in-situ modification of liposomes, in which a lipid analog bearing
a terminal alkyne group was used for chemoselective conjugation of molecules
containing an azido group. The application of this efficient conjugation method
has been extended for the attachment of ligands for liposome targeting, 42 and
decoration with DNA to enable the study of DNA-mediated bilayer fusion and
docking.43 Recently, in 2014, Smyth and co-workers described a protocol for
functionalization of exosomes with alkyne groups. Exosomes are membrane
vesicles 30−100 nm in diameter carrying blood, urine, and saliva, present in
almost all cells. They participate in cell-to-cell communication and can be
engineered to deliver protein, mRNA, and miRNA cargo molecules to recipient
cells in vitro and in vivo. Here, they first successfully modified the exosomes with
alkyne groups and next employed copper catalyzed azide-alkyne cycloaddition
(click chemistry) for bioconjugation of small molecules and macromolecules to
the surface of the exosomes.44
8

On the other hand, copper-free click chemistry using a strained cyclooctyne
moiety offers advantages since it does not require any added metal catalyst. For
instance, Bostic and co-workers first reported membrane functionalization using
copper free click chemistry employing azido tagged synthetic lipid.45 Blenke et al
successfully conjugated a small molecule azide with liposomes, and a number of
ligands were coupled per liposome at a reasonable reaction rate. 46 They
demonstrated the conjugation of a larger azide-modified protein and the number
of protein ligands coupled was found to be sufficient for liposome targeting to
cells. Essentially, their study revealed the site-specific conjugation of protein
ligands to liposomal surfaces via SPAAC.
Finally, the Staudinger ligation has found numerous applications for
bioconjugation since it is a high yielding reaction at room temperature in an
aqueous medium with high specificity. Zhang et al developed liposomal surface
functionalization through the Staudinger ligation reaction employing lactose as a
model carbohydrate.47 Here, the reaction conditions did not alter the integrity of
the bilayers in terms of liposome size and leakiness and provided perfectly
functional vesicles. The reaction was performed under mild conditions in
aqueous buffers without a catalyst, in high yields and with reasonable reaction
times. For this, they synthesized an unprotected lactosyl derivative carrying an
ethyl spacer functionalized with an azide group followed by derivatization to
generate glycosylated liposomes. Consequently, the Staudinger ligation reaction
between liposomes bearing synthetic anchor lipids with terminal triphosphine and
9

the azido group on lactosyl analogs enabled the liposome decoration. This
flexible approach can be widely used for the ligation of water soluble molecules,
can tolerate many chemical functional groups, and is expected to be convenient
for the coupling of other potential ligands to liposomes.
1.3 Passive Targeting Using Stealth Liposomes
Passive targeting of liposomes during drug delivery is driven by the inherent
selectivity of liposomes for entering tumor cells, which is a product of the
enhanced permeability and retention (EPR) effect. Normal capillary gaps around
endothelial cells are 5-10 nm,48 while carcinomas and other neoplastic or
inflamed tissues have a much larger gap area. Maeda et al. recently explained
biological aspects of how and why the blood vessels around cancer cells have an
increased porosity that allows liposomes up to 400 nm or greater to accumulate
around the tumorous and inflamed tissue.49 In addition, recent studies have
demonstrated how biocompatibility, surface charge, and circulation time can be
utilized to magnify the EPR effect in targeting diseased cells with liposomes.
Initial studies have suggested that a neutral to a slightly cationic charge of the
liposomal surface is optimal for exploiting the EPR effect, but more in-depth
research is required.6
The enlarged capillary gaps surrounding tumors and inflammation sites 50
associated with EPR can be accessed by nanoparticles around 100 nm in
diameter, which are considered as ideal. Nevertheless, these liposomes will be
recognized by opsonins, a class of serum proteins that non-covalently bind to the
10

surfaces of larger nanoparticles, marking them for phagocytosis beforehand and
clearance via the reticuloendothelial system RES, also referred to as the
mononuclear phagocytic system (MPS), unless carriers contain any camouflage
that can circumvent the body’s immune responses. Shielding nanoparticles from
opsonins is one good way to increase the circulation of liposomal drugs. This
concept eventually led to the idea of shielded (aka stealth) liposomes that use
PEG chains, which are chemically introduced at the surface of the nanoparticle to
discourage binding of opsonins, thereby opposing the ability of the RES to
remove the nanoparticles from the blood stream. It is noteworthy that some
research has suggested that the increase in circulation time in PEGylated
liposomes is not related to opsonin interference, but rather due to simply
decreased liposomal aggregation, a known feature of PEGylated vesicles.51
Moreover, increasing circulation time allows for the EPR effect to recruit
liposomal drugs to angiogenic sites but it also enhances drug exposure to other
healthy tissues.52
Figure 1.3 describes two popular PEG coatings: the brush mode and
mushroom-like globular PEG coating. Li and co-workers demonstrated a
formulation for brush mode with >8 mol% PEG that is ideal for total protection
from opsonization52 even though previous studies have shown that PEGylation
above 9 mol% will result in lateral repulsion of the brush-like PEG morphology,
destabilizing the membrane.53 Noble et al. reported a formulation for a mushroom
configuration where 5-9 mol% of PEG(2000) is utilized that completely masks the
11

vesicles from opsonins, escaping the RES and allowing for liposomal
accumulation.5 PEGylated liposomes and other nanoparticles are commonly
formed by incorporating PEG-lipids or PEG-polymers and formed via selfassembly. Many PEGylated lipids, including those with different lengths of PEGchains (i.e. PEG(2000) and PEG(5000)) connected to lipid anchors such as PE
are commercially available. This is true for many nanoparticles as well. PEG
groups can be post-inserted, as long as the appropriate functional group is
expressed on the outer membrane after self-assembly.

Figure 1.3: Two popular PEG morphology used on liposomal membranes:
high density ‘brush’ mode (left) and low density globular ‘mushroom’ mode
(right).

It is important to note that these two strategies (self-assembled modification
and post-modification/post-insertion via a synthetic handle) are the primary
means by which liposomal surfaces are functionalized for targeting and cargo
release as well. Although PEGylated liposomes stealthily evade the immune
12

system, eventually they accumulate in the tumor interstitial space as a result of
the EPR effect. PEG coatings inhibit liposome-liposome membrane aggregation,
which is beneficial for opsonin evasion and increases circulation time of
liposomal nanodrugs. Nevertheless, for the same reason, PEG coatings inhibit
endocytosis and confirm delivery of liposomal payloads when PEGylated
nanodrugs reach the tumor interstitial space.
1.4 Directed Delivery using Targeting Groups
In delivering drugs to cancer cells, generally, proteins that are overexpressed
on the cell surface due to disease onset are targeted to achieve selectivity. Very
often it has been noticed that cancer cells are enriched in certain protein classes,
receptor proteins of similar types are overexpressed concurrently in one strain of
cancer or there is variably among different types. For example, αβ integrins are
one novel class of transmembrane glycoproteins overexpressed in tumors that
can be exploited as a stimulus for targeted nanodrugs. 6 The α5β1 receptor is
also found to be overexpressed in breast cancers and can be targeted. For this,
generally, a fibronectin-mimetic peptide is incorporated into liposomal drugs to
decorate the nanodrug surface membrane and deliver it to cells, providing a
promising therapeutic strategy.54 This protocol exhibits minimum cytotoxicity
comparable to that of the free drug in vitro and can be considered a promising
sign when evaluating the clinical potential of nanodrugs. Cell surface receptors
are targeted by a number of commonly used antibodies.55
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Estrogens,

antibodies

against

progesterone

and

HER2

have

been

incorporated into liposomal drug formulations to selectively target breast cancer
tissues. For targeting ovarian cancer cells where epidermal growth factor
receptors (EGFRs) are overexpressed, EFGR-targeted monoclonal antibodies
are doped into liposomal formulations. Canonical estrogen receptor (ER) is
another example of an over-expressed protein in breast cancer. To target the ER
effectively, drug-loaded liposomes are formulated with ER antagonist tamoxifen
into the membrane. Nagasenker and co-workers formulated liposomes with the
lipophilic cancer-preventative tamoxifen and encapsulated doxorubicin using an
ammonium sulfate gradient. This formulation of stealth nanoparticles displayed
promising results since these liposomes can encapsulate tamoxifen and
doxorubicin to decrease the dosage of doxorubicin needed and also actively
target the drug to breast cancer. Moreover, estrone is another promising
targeting moiety for ER, and liposomal surfaces can be decorated with estrone
via conjugation to PEG linkers. Using this PEG-linked targeting strategy,
accumulation of doxorubicin-loaded liposomes was 24 times higher than the free
drug using this PEG-linked targeting strategy. Another antibody, anti-CXCR, was
associated with drug-loaded liposomes using dioleoyl phosphoethanolamine-Ndodecanoyl (N-dod-PE) to target a specific chemokine receptor (CXCR4).56
1.5 Drug Releasing Techniques
Stimuli sensitive nanoparticles (SSNs) are engineered to change in
composition

or

conformation

upon

exposure
14

to

cellular/extracellular

or

intrinsic/extrinsic stimuli which trigger the release of contents selectively at
diseased tissues. This change in composition/conformation brings about
alterations in the physicochemical and/or drug release properties of these
systems. Thus, SSNs demonstrate a “load-and-release” effect either due to
attached modalities or to the components themselves. The key benefit of using
lipids, polymers and macromolecules is that they intrinsically possess the
dynamic properties that are favorable for generating SSN composite materials.
Thus, it is crucial to have SSNs bearing sharp physical and chemical sensitivities
to instigate release of associated cargo upon a subtle change in surrounding
conditions. These physical and chemical properties of SSNs greatly influence the
complex physicochemical properties of membranes such as bilayer stability,
phase separation, and fluidity in suitable environmental circumstances. Once the
nanocarriers enter their desired site of action and are exposed to the specific
stimulus that they are tuned for, the bioactive cargo is freed in a manner
dependent on its method of inclusion. Entrapped bioactive molecules are
commonly released via structural changes in the carrier architecture (i.e.
cleavage of the shell, charging of functional groups or carrier degradation).
Bioactive payloads can also be directly conjugated to the nanocarrier, for which
breakage of the linker between the bioactive molecule and the carrier is the
mechanism of triggered release in this instance. Stimuli sensitivity either exists
inherently in the nanocarrier building blocks or can be imparted chemically. The
unique biochemistry of diseased cells, such as cancers, helps to enhance the
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responsive effects of SSNs and can eventually lead to precise temporal and
spatial drug delivery, improving therapeutic efficacy with diminished off-target
effects.
1.5.1 Internal Stimuli Triggered Release
Stimuli-sensitive drug delivery, or smart delivery, is an extension of the
concept of active targeting that advances the goal of delivering the cargo at the
diseased site and over the desired time frame. Stimuli-sensitive drug delivery or
smart delivery systems use a local stimulus or pathological change occurring in
the targeted tissue as a trigger for release. For example, lower pH and higher
temperatures are very common traits of tumors and other inflamed tissues
compared to most healthy tissues. These factors are termed intrinsic stimuli
(Figure 1.4) since they result from conditions characteristic of diseased tissues.
Furthermore, greater redox potential is generally observed in cancerous tissues
due to altered enzyme expression, which may be present in small quantities or
may not be present at all in normal tissues. However, the differences in these
intrinsic properties of the diseased cells only vary slightly from ideal physiological
conditions. For example, the average extracellular pH of cancer cells has been
measured as 6.56.9 compared to 7.27.4 for normal tissue.57,

58

. To release

drug species from PEGylated liposomes, this property of cancer cells is generally
exploited. There are cleavable PEG moieties that can be removed from the
membrane to allow for endocytosis. For example, liposomes with pH-sensitive
diortho ester bonds by which PEGs are linked or thiol-conjugated PEGs will
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cleave their PEG camouflage in acidic environments,59 including the vicinity of
tumors. Other modified PEG polymers will cleave in acidic environments as well,
such as polyglutamic acid–graft-methoxy polyethylene glycol (PGA–g-PEG).60
The biodegradable disulfide bond can also be used to imbue liposomes with
sheddable PEG coatings.61

Figure 1.4: Drug releasing techniques utilizing external or internal stimuli to
release entrapped drug at desired site.

1.5.2 External Stimuli Triggered Release
On the other hand, external stimuli can be employed to trigger release in the
region of interest such as by applying local heat to induce hyperthermia or
ultrasound or near infrared light to bring about local delivery of cargo. This
approach can be advantageous in that it is not dependent on the properties of
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the targeted cells and can be administered in a more localized manner, although
the delivery of stimuli to the desired location can be challenging.62
1.6 Light-Induced Releasing Technique
Photo-induced alterations in the properties of lipid carriers have become a
popular approach for triggered release of contents. These systems commonly
involve a self-assembled system that undergoes a change in structure upon
photocleavage or cleavage of a linker by which a drug is covalently attached to
the nanocarrier.63-65 Photo-induced delivery applications benefit from the
capability to apply irradiation in a temporally and spatially controlled manner
using a remote source. However, one of the shortcomings of these light triggered
releasing techniques with one-photon photocleavable chromophore is that the
ultraviolet (UV) wavelength range employed for excitation discourages their
applicability since many biomolecules absorb irradiation in this range, leading to
their photodecomposition as well as the inability of the beam to penetrate tissue.
Therefore, it is advantageous to develop photoinitiated systems that are activated
in the near-IR (NIR) range, which benefit from enhanced penetration and
decreased damage to cells.
The properties of light that can be easily regulated render irradiation as a
suitable means of release. These properties include timed release of lipid carriers
at desired sites, control over properties such as wavelength, intensity, duration,
and localization.62 Light is used for many applications, including crosslinking in
protein–lipid binding and photoaffinity labeling.66 It can also be utilized for the
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activation or deactivation of certain molecules by decomposing photochemicallyresponsive moieties. For this reason, light protecting groups (LPGs) have been
synthesized. One of the more studied LPGs is the 2-nitrobenzyl group.67 Other
groups include 7-nitroindoline, coumarin-4-ylmethyl, p-hydroxyphenacyl, and
nitrophenethyl (Figure 1.5).68

Figure 1.5: Examples of photocaging groups which aid in light triggering
release of payloads from drug delivery vehicles.

Recently, Dong and co-workers utilized a photocleavable coumarin
chromophore to synthesize a novel two photon-sensitive amphiphile with two
alkynyl groups as a two-photon-cleavable segment (Figure 1.6).69 This design of
stable assemblies of surfactants was found to exhibit potential for dose-controlled
triggered release in biomedical applications. The main advantage is that either
UV light (365 nm) or a NIR pulse laser (800 nm) can be applied for photolysis of
the coumarin units to expose the cargo. The 2-nitrobenzyl photocleavable group
has also been widely applied to construct light-triggered switchable lipid systems.
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Figure 1.6: Examples of lipid analogs developed for photochemically
induced drug release, including O-nitrobenzyl in NVOC-DOPE (1.1),
dithianes (1.2) and coumarin (1.3).
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For

example,

Zhang

et.

al.

synthesized

nitroveratryloxycarbonyl-PE,

that

is

a

caged

a

novel

derivative

lipid,
of

6-

dioleoyl

phosphatidylethanolamine (DOPE), for assembling bionanocarriers.70 DOPE is a
non-bilayer lipid at physiological pH that adopts inverse cubic and inverse
hexagonal structures. On the other hand, N-acylated PEs are negatively charged
phospholipids and can form kinetically stable liposomes. Photolysis of NVOCDOPE (1.1) destabilizes the lipid bilayer, which eventually leads to liposome
disruption and release of encapsulated payloads. This is a promising
photochemically triggered delivery system to initiate a vast range of dynamic
membrane processes, such as membrane fusion and the activity of enzymes
embedded within membrane bilayers. However, the UV light requirement to
induce photocleavage of lipids is a technical drawback, limiting the ability to
monitor the subsequent membrane process. Two-photon chromophores are a
promising solution since excitation using IR wavelengths is less detrimental to
biological systems and is more applicable for biomedical delivery protocols.
Nagasaki et al. synthesized a cationic lipid bearing an o-nitrobenzyl moiety as a
photocleavable spacer between its hydrophobic and hydrophilic regions, where
the polar hydrophilic sections constituted of either the amino acid residue lysine
or

arginine.71

They

examined

the

transfection

efficiency

of

resulting

photoresponsive lipoplexes on COS-1 cells and found enhanced transfection as
a result of photochemical decomposition of lipids compared to transfection
without irradiation.
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1.7 Importance of Lipids in Cell Membranes
Cell membranes not only separate the interior of the cell from the extracellular
space, but also form the boundary between the internal compartments of
eukaryotic cells, including the nucleus and cytoplasmic organelles. Cell
membranes are crucial for maintaining the rigid structure of the cell and are
responsible for multifaceted functions that regulate cell activities. All cell
membranes are comprised of a common structural organization: phospholipid
bilayers with associated proteins. These membrane proteins play important roles
in many specialized functions; some act as receptors that allow the cell to
respond to external signals, some are responsible for the selective transport of
molecules across the membrane, and others participate in electron transport and
oxidative phosphorylation. On the other hand, phospholipid compositions in cell
membranes vary among different compartments depending on lipid metabolism
and trafficking. Lipid molecules with two hydrophobic fatty acid chains linked to a
phosphate-containing hydrophilic head group are classified into two categories
based on their functions in membranes: bulk lipids and signaling lipids. As the
name implies bulk lipids represent the primary component of cell membranes,
whereas signaling lipids present in much smaller percentages serve as functional
molecules and site-specific ligands. These signaling lipids include phosphatidic
acid (PA), diacylglycerol (DAG) and the family of phosphatidylinositol
polyphosphates (PIPns). These lipids have been actively explored and
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investigated to understand their roles in crucial processes such as membraneprotein interactions.
Protein-membrane binding interactions represent key molecular recognition
events that control vital cellular processes including signal transduction events,
viral cell entry as well as other processes, and aberrations in binding interactions
trigger several diseases.72 For instance, fluctuations in DAG have been linked to
the onset of cancer73-75 and diabetes,75 etc. Moreover, phosphatidylinositol 3kinase (PI-3K) converts PI-(4,5)-P2 to PIP3, the latter of which binds and activates
Akt, finally activating several events that regulate the cell cycle. The reverse
conversion is promoted by PTEN. Consequently, enzymes that interconvert PI(4,5)-P2 and PIP3 are among the most commonly mutated proteins in cancer.76
Furthermore, it has been determined that phosphatidylserine (PS), normally
present at the inner leaflet of the plasma membrane, is translocated into the
outer leaflet during apoptosis and the onset of many cancers. This results in PS
acting as a biomarker that could be exploited for the selective detection or
targeting of cancer cells. Due to the key roles that lipids play in cancer and other
diseases, it is necessary to characterize binding activities to fully understand their
biological complications.
1.8 Metabolic Labeling by Bioorthogonal Reporters
A growing area of chemical biology strives to probe biomolecules in living
systems by using bioorthogonal chemical reactions (that is, reactions that do not
interfere with biological processes). Such reactions must have fast rates under
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physiological conditions with high specificity in the presence of surplus complex
functional groups. Metabolic labeling refers to methods in which the endogenous
biosynthesis and modification machinery of living cells is used to convert
substrate analogs into labeled versions of natural biomolecules. Often, the tag
that is incorporated into the substrate derivative is a clickable group, which
enables their selective modification with fluorescent dyes or affinity reagents for
analysis. This facilitates the detection of the localization and function of
biomolecules within cells, which is challenging because of the vast complexity of
metabolites present in cellular systems. However, labeling with genetically
encoded reporters frequently is incapable of monitoring many biomolecules, such
as nucleic acids, lipids, and glycans, as well as various posttranslational
modifications.28, 77 Here, labeling these biomolecules in living systems employing
biorothogonal chemical reactions has become appealing and expedient. The
bioorthogonal chemical reporter strategy involves the incorporation of unique
functionality into targets of interest, followed by chemical labeling with a smallmolecule probe (Figure 1.7). Ideally, the substrate analog containing a chemical
reporter (green circle, Figure 1.7), in this case an azido group, is fed to cells for
incorporation into products through normal metabolic pathways. This is
accomplished by appending the reporter to substrates that can be used by the
cell's own metabolic machinery. Next, these labeled target products are detected
using a bioorthogonal reaction.

24

Figure 1.7: Strategy for metabolic labeling of biomolecules in living
systems. A chemical tag (i.e. azide) linked to a substrate (green circle
shape) is incubated with cells to produce labeled products through normal
cellular metabolism. Next, the appended tag can be modified via
bioorthogonal reaction with an exogenously delivered reagent (brown
asterisk). This allows for the selective labeling and detection of tagged
products.
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A common strategy for post-labeling involves click chemistry since the azide
and alkyne moieties are small and thus minimally perturb the natural function and
modification of probes. For example, amino acids bearing bioorthogonal
functional groups can be accepted by the translational machinery of a cell and
incorporated into proteins.78,

79

Here, labeling of proteins using radiolabeled

amino acids and in cell cultures (prokaryotic or eukaryotic) has been popular.
This technique results in a measurable incorporation of radioisotopes in proteins,
which

can

be

easily

detected

by

scintillation

counting

or

mass

spectrophotometry.80 Furthermore it has been reported that cell selective protein
labeling is possible with azidonorleucine.81 In 2014, Smeekens and co-workers
described a unique approach to analyze cell surface

N-glycoproteins

comprehensively and site-specifically.82 For this purpose, they combined
metabolic labeling, copper-free click chemistry, and mass spectrometry (MS)based proteomics methods together and cells were fed a sugar analog
containing an azido group, N-azidoacetylgalactosamine. Azido functionalized
glycoproteins on the cell surface were then clicked to dibenzocyclooctyne-sulfobiotin via copper-free click chemistry under physiological conditions. Next, protein
extraction followed by digestion was performed, followed by click chemistry to
append biotin to labeled products, and finally glycopeptides with the biotin tag
were enriched by NeutrAvidin conjugated beads. Deglycosylation of enriched
glycopeptides was carried out by peptide-N-glycosidase F in heavy water and
eventually these products were tagged with 18O for MS analysis.
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Similarly, functionalized monosaccharides can be introduced into cell surface
glycans by means of promiscuous enzymes in the biosynthetic pathways of these
biopolymers.26 Laughlin and co-workers reported labeled glycans by metabolic
glyco-engineering and bioorthogonal copper-free click chemistry. For this
purpose, first the cells or organisms were treated with azido tagged sugar,
tetraacetylated N-azidoacetyl-D-mannosamine (Ac4ManNAz) and incorporated by
the glycan biosynthetic machinery to generate various glycoconjugates, which
are ultimately located on the surface of the cells. Regardless of the route
exploited, each enzyme involved in the installation process must tolerate the
unnatural motif. For this reason, typical biophysical probes, such as fluorescein,
cannot be used as direct modifications to metabolic substrates (that is, amino
acids, lipids or sugars) as their relatively large size would interfere with enzymatic
transformations. A small functional group is more likely to be tolerated by
metabolic enzymes. Thus, to date, bioorthogonal chemical reporters have been
non-native combinations of endogenous functionality (as discussed earlier) or
small, abiotic functional groups that can slip through existing biosynthetic
pathways. Therefore, metabolic labeling can be an advantageous tool for
exploring production and trafficking of different biomolecules in cell systems that
eventually will illuminate light on crucial cellular processes.
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CHAPTER TWO
A CLICKABLE AND PHOTOCLEAVABLE LIPID ANALOG FOR
CELL MEMBRANE DELIVERY AND RELEASE
The scientific data used in this chapter has been published by the authors:
Shahrina Alam, Daiane S. Alves, Stuart A. Whitehead, Andrew M. Bayer,
Christopher D. McNitt, Vladimir V. Popik, Francisco N. Barrera, and Michael
D. Best
Bioconjugate Chem. 2015, 26(6), 1021-31
2.1 Introduction
Lipids are characterized as attractive candidates for the delivery of drugs and
imaging agents since they are biocompatible and they are capable of targeting
molecules to cells through actions including insertion and fusion involving cellular
membranes.83-87 Therefore, advanced methods for covalent conjugation of active
molecules onto lipids and liposomal surfaces have become popular in recent
years. In this regard, bioconjugation approaches that allow for the selective
attachment of molecules within the intricate environments of biological samples
are particularly beneficial.11-13 This concept has been applied to covalently attach
drug moieties onto lipid assemblies such as liposomes, enabling their anchoring
onto the membrane surface and subsequent delivery to cells. Additionally, it is
convenient to apply a controllable technique when molecules are covalently
conjugated to the lipids to trigger the release of the active molecule from the
membrane surface.
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Recently, biorthogonal methods, such as click chemistry reactions, have been
explored for the derivatization of lipids and membranes to attach molecules and
exploit the selectivity and fast kinetics of these reactions under ambient
conditions.

11-13, 88-90

copper-catalyzed

Initial methodologies have focused on developing the

azidealkyne

cycloaddition

(CUAAC)

for

membrane

derivatization.40, 43, 91-96 However, this reaction has some serious concerns as the
prerequisite copper catalyst can cause the decomposition of lipid membranes.97
For this reason, copper-free click chemistry has emerged as a powerful tool for
lipid and membrane derivatization45,

98, 99

. Applying this concept, our group

reported functionalization of membrane surfaces using copper-free click
chemistry

employing

membranes.45

In

an

azido-lipid

addition,

conjugate

researchers

have

to

derivatize

liposomal

successfully

attached

thrombomodulin proteins to liposomes to enhance activity,98 and achieved the
targeting of liposomes bearing trans-cyclooctene moieties to cancer cells via the
pH low insertion peptide (pHLIP) via bioorthogonal reactions.99 The strain
promoted azide-alkyne cycloaddition (SPAAC) is more suitable than other
bioorthogonal protocols that are available. It is more advantageous than the
Staudinger ligation method since neither alkyne nor azide group is readily
oxidized unlike phosphines. Moreover, dibenzocyclooctyne reagents 100 have
been developed as robust reactants with desirable kinetic properties, and in
particular azodibenzocyclooctyne reagents, termed ADIBO or DIBACO, benefit
from fast kinetics and ease of synthetic preparation.30 This ring strained
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cyclooctyne species promotes the copper free [3+2] dipolar cycloaddition without
any toxic copper catalyst and exhibits comparable kinetics to the Cu-catalyzed
reaction.
2.2 2-Nitrobenzyl Photoactivating Group in Light Triggering Release
Techniques
Photo-induced release systems commonly revolve around a self-assembled
system that undergoes a change in structure upon photocleavage or cleavage of
a linker by which a drug is covalently attached to the nanocarrier.63-65 Lightinitiated release is favorable as it is a general approach that can be controlled in
a spatially resolved manner to stimulate release at desired target sites, and the
2-nitrobenzyl groups is among the best studied for photoinitiated bond
cleavage.101 Prior work involving the incorporation of photocleavable groups into
lipids has focused on light-initiated release of molecules from liposomes.102-108
The strategy adopted here is straightforward; molecules such as drugs are noncovalently encapsulated in the liposome and release is instigated by
decomposition or disruption of the membrane. Nevertheless, non-covalent
encapsulation of drug moieties often leads to significant background leakage,
and therefore it can be desirable to covalently attach target molecules to lipids
prior to triggering the release through bond cleavage.
Recently, our group employed the o-nitrobenzyl moiety to synthesize the
biologically-inert

and

photocleavable

PC

analogue

NB-PC,

where

the

photosensitive 2-nitrobenzyl group was embedded within the acyl chain at the sn30

2 position to produce a photocleavable lipid with a structure similar to that of
natural PC.93,

108

This lipid was constructed in such a way that photocleavage

would cause disruption of the sn-2 acyl chain, ultimately culminating in the
formation of an LPC product that is a non-bilayer lipid, thereby overall perturbing
membrane properties. Photolysis studies detected the release of the hydrophobic
dye nile red solubilized by the liposome by monitoring fluorescence with a series
of liposomal formulations. We studied different liposomes formulations with
different percentages of NB-PC, PC, PE, cholesterol, and PEG-PE and
established minimal background release in controls, which indicated that release
efficacies correlated with the amount of NB-PC incorporated. Moreover, release
was only minimally impacted by the inclusion of the lipids PE and cholesterol that
possess disparate membrane properties. As a result, nile red could be released
from liposomes composed of a wide variety of lipids through incorporation of NBPC.
2.3 Design of Photocleavable and Clickable Lipid
In this project, we set out to design a lipid delivery system that contains both a
copper-free clickable group for the attachment of molecules onto the liposome
surface as well as a photocleavable group for release after targeting. The
resulting compound is 2.1, containing an o-nitrobenzyl group that links the
glycerolipid membrane anchor to the ADIBO unit by which cargo is attached. A
schematic for cellular delivery and release using this compound is depicted in
Scheme 2.1, which was initially assessed through the delivery of fluorescent
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dyes using compound 2.1. Compound 2.1, either in individual or liposome form,
can be incubated with cells, leading to cell entry through processes such as
endocytosis or membrane fusion. Afterward, bioorthogonal copper-free click
reaction can be performed to target azide-tagged molecules to cells by exploiting
the ADIBO unit of 2.1. As an alternative, targeting groups could be clicked onto
2.1 prior to cell delivery or conjugation could be performed using liposomes
containing 2.1 for subsequent delivery and fusion with cell membranes. In the
example depicted in Scheme 2.1, derivatization with Azide-Fluor 488 (2.14)
leading to triazole-linked product 2.15 was exploited for fluorescence-based
analysis. Next, photocleavage through irradiation was accomplished with 350 nm
light, which results in release of the clicked molecule either on the inside of cells
or in the proximity of cellular membranes. This follows through the traditional
cleavage of the benzylic position to produce aldehyde-lipid byproduct 2.16 as
well as the released triazole-linked conjugated molecules, in this case 2.17.
2.4 Synthesis of Lipid Analog
The synthetic route to clickable and photocleavable lipid 2.1 entailed coupling
of alkyne-bearing 2-nitrobenzene 2.2 to azido-lipid scaffold 2.3 via click
chemistry, followed by reaction with ADIBO-carboxylic acid 2.4 (Scheme 2.2).
For the synthesis of alkynyl 2-nitrobenzene 2.2, we followed previously reported
literature by first protecting the amino group of 4-aminomethylbenzoic acid (2.5)
as tert-butyloxycarbonyl (Boc) group to 2.6.
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Scheme 2.1: Delivery of lipid analog 2.1 to cell membranes, followed by
click reaction to attached functionality and later photocleavage to release
the targeted cargo.

Next, a nitration reaction was carried out to synthesize 2.7. the Boc protecting
group was then exchanged to the trfiluoroacetate moiety of 2.8. These initial
three steps benefitted from previously reported procedures.104 Carboxylic acid
2.8 was then coupled to propargylamine to introduce the clickable alkyne handle
of 2.2. While we have previously reported azide- tagged lipid 2.3,109 a modified
synthesis was developed to enhance yields by avoiding volatile intermediates.
For the current route, S-glycerol acetonide (2.9) was converted to tosylate 2.10,
as previously reported109, followed by acetonide deprotection to diol 2.11, azide
displacement to 2.12, and acylation with two stearic acid moieties to produce 2.3.
Next CUAAC was employed to couple compounds 2.2 and 2.3 to form 2.13,
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which is beneficial due to synthetic facility. Furthermore, prior evidence has
suggested that the polarity of the triazole headgroup may make this moiety an
effective polar lipid headgroup mimic that lacks the charge that makes
phospholipids difficult to purify and characterize. 109, 110 Finally, the Boc protecting
group of 2.13 was deprotected using trifluoroacetic acid (TFA) and the resulting
amine was coupled to ADIBO-carboxylic acid 2.13, synthesized as previously
described,30 to access 2.1. Compound 2.4 was generously provided by Dr
Vladimir Popik’s group at the University of Georgia, and was synthesized by
Christopher Mcnitt in that group.

Scheme 2.2: Synthesis of a lipid analog 2.1 with a cyclooctyne and 2nitrobenzyl group.
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2.5 Solution Phase Fluorescence Detection of Liposome Derivatization
Results
We first studied lipid analog 2.1 by examining its efficacy for functionalizing
liposomes through copper-free click chemistry. Liposome modification was tested
through the reaction of liposomes with 3-azido coumarin, which was synthesized
by Stuart Whitehead in the Best group. This is a fluorogenic dye that is not
initially fluorescent, but for which emission properties are activated upon
formation of the triazole ring via the click reaction. Here, unilamellar liposomes
(extruded to ~200 nm) were prepared composed of 96 % PC and doped with 4%
lipid 2.1. Standard procedures including hydration and extrusion as well as
dynamic light scattering were used to formulate and characterize liposomes.
Next, derivatization of liposomes with 2.18 was assessed in solution using a
fluorimeter to track enhanced fluorescence resulting from click chemistry. 111 The
fluorescence of the liposomal solution increased after addition of 2.18 and finally
plateaued after ~ 40 minutes, indicating the azido group of 2.18 successfully
clicked onto cyclooctyne group of lipid analog 2.1 (Figure 2.1). Liposomes
lacking 2.1 were additionally incubated with 2.18 as a control and fluorescence
was detected over the same time period as seen in Figure 2.1. In this case, only
a minor increase in fluorescence was observed, likely attributable to a slight
enhancement of the fluorescence properties of 2.18 caused by some insertion
into the hydrophobic membrane environment. This change in fluorescence of
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2.18 in the presence of membranes explains the double curve character of the
results seen from the study sample.
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Figure 2.1: Change in fluorescence of azido-coumarin 2.18 in the presence
of liposomes containing and lacking cyclooctyne lipid 2.1.

2.6 Microplate Fluorescence Liposome Derivatization Studies
Although the solution liposome assay is a convenient method for detecting
fluorescence as a result of liposomes conjugation as a function of time, this study
suffers from the background fluorescence due to 2.18 in the presence of
membranes lacking 2.1. Thus, we introduced a surface immobilization assay as
an alternative method for detecting liposome conjugation via 2.1 (Scheme 2.3).
Our

group

has

previously

developed
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a

fluorescence-based

liposome

immobilization assay to monitor protein-membrane binding interactions.45 This
surface-based analysis offers a beneficial strategy for characterizing receptorligand binding interactions that has been exploited for the study of DNA112,
protein and peptide113, and to a lesser extent, lipid114 binding interactions.

Scheme 2.3: Principle of streptavidin coated microplate assay for
immobilization of liposomes using reaction with 3-azidocoumarin to
characterize membrane derivatization.

Moreover, for this immobilization assay, it has been demonstrated that
liposomes are successfully anchored onto the surface of the microplate, and
immobilization is driven by an incorporated biotin-lipid conjugate rather than
through non-specific binding.45 In addition, a dye leakage assay was used to
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show that liposomes remain intact on the surface. The strategy involves the
incubation of the biotinylated liposome, which is immobilized onto the
streptavidin-coated microplate. Another significant aspect of this assay is that the
biotin anchor needs to be presented at some distance from the membrane
surface, as liposomes are known to degrade upon contact with and fuse to
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Figure 2.2: Change in fluorescence of azido-coumarin 2.14 in the presence
of microplate-immobilized liposomes following wash off of unreacted dye.

To apply this assay to assess derivatization of lipid 2.1, liposomes containing
this lipid were immobilized onto streptavidin-coated 96-well microplates through
incorporation of biotin-functionalized phosphatidylethanolamine analog 2.19,
previously synthesized and reported by our group.109 Following incubation of
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liposomes with 2.18, the immobilization step enabled the removal of unreacted
dye from the surface-bound liposomes after washing the wells with buffer
solution. Liposome derivatization was assessed using a fluorescence microplate
reader (excitation filter 360 ±40 nm, emission filter 440 ± 40 nm) to detect the
enhanced fluorescence of 2.18 upon triazole formation with 2.1 incorporated into
liposomes. As is evident from Figure 2.2, this experiment clearly displayed a
dose-dependent response as an increase in liposome concentration leads to
higher fluorescence values due to formation of fluorescent click conjugate upon
reaction of 3-azido coumarin. This microplate based study confirmed successful
liposome conjugation via copper-free click chemistry with lipid 2.1. In addition,
the removal of unreacted dye yields a more traditional curve for product
formation compared to the results obtained from the prior solution studies of
liposome modification.
2.7 Fluorescence Imaging and Flow Cytometry Analysis of Fluorescence
Labeling and Photocleavage using Saccharomyces cerevisiae Cells
With successful results from liposome studies, we next set out to assess
delivery and release using live Saccharomyces cerevisiae cells (Scheme 2.1).
This study is aimed at the examination of the lipid analog 2.1 for delivery and
release of species in live cells using fluorescence microscopy. Fluorescence
microscopy, a versatile technique, is widely used to examine a number of
essential phenomena such as cellular delivery. In these experiments, cells were
first cultured, incubated with 2.1, the fluorophore labeled species of interest was
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added and, and the cells were localized on glass slides and cover glass by a
fixation agent. By means of a xenon or mercury lamp, the system was irradiated
with UV light. The emitted light was then imaged through a microscope objective.
Recently, Neef et al.115 reported the fluorogenic labeling of alkyne-containing
phosphatidic acid (PA) probes. Delivery of these lipid probes to cell membranes
was confirmed by fluorescence microscopic images. Similarly, our study
assesses the delivery of the fluorescent lipid analog to membranes and release
of cargo. Therefore, we next set out to assess delivery and release using live
Saccharomyces cerevisiae cells (Scheme 2.1). To do so, yeast cells were grown
in the presence and absence of 2.1 in the glucose medium. After growing cells
overnight up to OD600 values (optical density of cells at 600 nm) of 1.2, cells
were incubated with commercially available Azide-Fluor 488 (2.14), followed by a
number of washes and finally cells were fixed onto slides. Next, these cell
samples were analyzed using a fluorescence microscope to assess delivery of
the fluorophore to cells, for which representative images are shown in Figure
2.3. Here, cells grown in the presence of lipid 2.1 (Figure 2.3A) result in
significant fluorescence compared to control studies lacking 2.1 (Figure 2.3B),
both of which were incubated with Azide-Fluor 488 and washed with 25%
DMSO/water to remove unreacted dye. These figures showcase the successful
delivery of lipid 2.1 to cells and subsequent derivatization.
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Figure: 2.3 Fluorescence images of yeast cells after click reaction and
photocleavage.
A. cells grown in the presence of 2.1, B. cells grown in the absence of 2.1,
and C. cells grown in the presence of 2.1 and irradiated for 12 hours, each
of which was washed to remove unbound dye prior to imaging. D-F.
Transmission Images showing cell population for the three experiments,
respectively.
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To assess release via photocleavage, cells were photolyzed using a Rayonet
photoirradiator for different periods of time. Next, cells were washed once with
5% DMSO in water and twice with 20% DMSO in water to remove unreacted dye
(not attached to lipid 2.1 embedded within cell membranes). After fixing the cells
with ice-cold methanol, they were subjected to confocal fluorescence
microscopy. A representative image in Figure 2.3C taken after 12 hours of
photocleavage demonstrates that fluorescence is significantly decreased
following photocleavage. Control studies in which the labeling dye was subjected
to irradiation conditions used for photolysis indicated that photobleaching was not
occurring as no decrease in fluorescence was observed (data not shown). In
addition, transmission images (Figures 2.3D-F) are included for the three
described images, respectively, showing the presence of cells in each sample.
For quantitative evaluation of delivery and release in vivo studies, we
employed flow cytometry-based analysis, with results shown in Figure 2.4.
Figure 2.4A illustrates a bar graph of fluorescence for control cells that were not
treated with 2.1 or 2.14 (unstained), study cells that were incubated with 2.1,
clicked with 2.14 and washed (stained), and stained cells after photocleavage for
1, 2, 3, and 12 hours followed by washing. From this graph it is evident that
clicked

cell

samples

exhibited

maximum

fluorescent

cells,

whereas

photocleavage yielded a decrease to 70%, 60%, 57%, and 42% of the original
fluorescence of the unstained sample after 1, 2, 3, and 12 hours, respectively.
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Figure 2.4: Results from flow cytometry of labeled cells for quantitative
analysis. A. Bar graph depicting fluorescence detected for cells not
treated with 2.1 (unstained), cells treated with 2.1 (stained), and treated
cells irradiated for 1, 2, 3, and 12 hours, each of which was washed prior
to fluorescence imaging. B. Flow cytometry results for cells that were
unstained (red), after click with 2.14 (blue), and after photocleavage for 3
(green) and 12 (orange) hours.
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In addition, representative plots of fluorescence signal observed from flow
cytometry analysis of the different described samples are shown in Figure 2.4B.
2.8 MTS Assay Results and Mass Spectrometry Evidence for Delivered
Camptothecin to T24 Cells
Finally, our last study was aimed at evaluating compound 2.1 for delivery and
release of an anti-cancer therapeutic with human cancer cells towards a real
world application of this compound as a drug delivery vehicle. Here, we were
interested in determining whether compound 2.1 would allow clicked cargo to be
released inside the cell and thus exhibit medicinal properties. Therefore, we
decided to employ camptothecin (CPT, 2.22), a potent anti-cancer drug that is
challenging to deliver due to its poor solubility. 116 To deliver this compound via
copper-free click chemistry, we designed clickable analog 2.20 containing an
azido-hexanoyl chain esterified to the free hydroxyl group of the drug (Scheme
2.4). Moreover, this analog enables triggered release without requiring
photocleavage since the ester linker can be hydrolyzed following cell entry by
intracellular esterases, thereby releasing camptothecin itself. For this purpose,
HeLa cells were incubated with PC liposomes doped with 6% of lipid 2.1 in the
presence and absence of camptothecin-azide 2.20 (CPT-N3). This experiment
was performed in collaboration with Daiane S. Alves in Francisco Barrera’s lab.
Here, liposomes containing 2.1 were incubated with CPT-N3 2.20 for attachment
onto the liposome surface, treated with cells, and cell viability was then assessed
through the MTS assay. This produced liposome-immobilized conjugate 2.21,
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which was confirmed by mass spectrometry. Camptothecin itself was studied
using a DMSO vehicle as a positive control, and all cell viability studies were
performed using a standard MTS assay. In these studies, liposomes containing
2.1 alone did not influence cell viability, but those that were pre-incubated with
added 2.20 ranging from 10-50 µM led to a dose-dependent decrease in living
cells (Figure 2.5). Compound 2.20 alone was not viable for studies since it is not
soluble in aqueous solution. These results demonstrate the delivery of
camptothecin to cancer cells using compound 2.1.

Scheme 2.4: Liposomal delivery of camptothecin to Hela cells.

These studies also explain the phenomena by which lipid 2.1 interacts with
membranes and where release occurs. Two possible mechanisms for release via
photocleavage could be responsible for delivery to cells. First of all, lipid 2.1
conjugated to cargo could use its hydrophobic tail to anchor onto the outer leaflet
of cell membrane, which would lead to a high local concentration of the drug
around the periphery of cells.
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Figure 2.5: MTS assay in human cancer cell line indicates that CPT-N3
reduces cell proliferation in a dose-dependent manner.
HeLa cells were treated with vehicle (Ct (-)-DMSO 0.01%), CPT (22, 50 µM),
Liposomes control (Lip) and liposomes pre-incubated with CPT-N3 22
(Lip+CPT-N3) at different CPT-N3 concentrations (10 µM, 25 µM and 50 µM)
for 48 hrs. Cell proliferation was measured by MTS assay and the graph
represents the percentage relative to the control CT(-). The results
represent the mean of 3 independent experiments. Statics t-test: * p<0.05
and ** p<0.001 two populations relative to CT (-). The error bars shown
correspond to the standard deviation.
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Alternatively, after being incorporated into the outer leaflet of cell membranes,
lipid 2.1 bearing cargo could flip across the membrane into the inner leaflet prior
to release. The second mechanism would be beneficial since lipid 2.1 could
facilitate the membrane translocation of the cargo, although this release process
is highly dependent on the properties of the cargo that is being delivered. Finally,
the liposomes could enter cells by endocytosis. The camptothecin esterase
release results provide evidence to support that this molecule conjugated to lipid
2.1 do enter cells since this would be required in order for the release by
esterase hydrolysis to occur. Delivery of CPT-N3 and hydrolysis by esterases has
been further confirmed after lipid extraction of the cells; cells incubated with 2.21
were lysed, extracted with hydrochloric acid (2N) and the aqueous non-lipidic
component was analyzed by mass spectrometry, which clearly showed a peak
for a derivative of camptothecin due to acidic hydrolysis at m/z value 341.80. This
peaks also observed when natural camptothecin (2.22) was subjected to the
same acidic hydrolysis.
2.9 Conclusion
After synthesizing lipid analog 2.1 containing a click reporter group and a
photocleavable moiety, we successfully demonstrated that it can be conjugated
when incorporated into liposomes via two different fluorescence assays involving
fluorogenic dye conjugation and a liposome immobilization assay. Fluorescence
microscopy studies corroborated by flow cytometry showed that this compound
could be exploited to deliver fluorescent cargo to cells, and subsequent
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irradiation with UV light triggered release. In drug delivery studies, the MTS
assay confirmed the delivery of camptothecin into Hela cells using lipid analog
2.1, leading to a dose-dependent decrease in cell viability. While this compound
was shown to be successful for delivery and release in vitro, the 2-nitrobenzyl
group in 2.1 absorbs light in the ultraviolet (UV) wavelength range that hinders its
applicability since many biomolecules absorb irradiation in this range, leading to
their photodecomposition as well as the inability of the beam to penetrate tissue.
Therefore, in the future we will design and develop two photon initiated systems
that are activated in the near-IR (NIR) range, which benefit from enhanced
penetration and decreased damage to cells.
2.10 Experimental
Reagents and solvents were generally purchased from Acros, Aldrich or
Fisher Scientific and used as received. PC (L-α-Phosphatidylcholine from
chicken

egg)

was

purchased

from

Avanti

Polar

Lipids,

Inc.

and

4(aminomethyl)benzoic acid was purchased from Chem Impex International. Dry
solvents were obtained from a Pure solvent delivery system purchased from
Innovative Technology, Inc. Column chromatography was performed using 230400 mesh silica gel purchased from Sorbent Technologies. NMR spectra were
obtained using Varian Mercury 500 and 600 spectrometers. Mass spectra were
obtained with JEOL DART-AccuTOF and ABI Voyager DE Pro MALDI mass
spectrometers with high-resolution capabilities. Optical rotation values were
obtained using a Perkin-Elmer 241 polarimeter. Liposome extruder and
48

polycarbonate membranes were obtained from Avestin (Ottawa, Canada).
Ultrapure water was purified via a Millipore water system (≥ 18 MΩ·cm triple
water purification system). 4-(((Tert-butoxycarbonyl)amino)methyl)-3-nitrobenzoic
acid (2.8)104

and 6-azidohexanoic acid (2.23)117 were synthesized from 4-

(aminomethyl)benzoic acid (2.5) and 6-bromohexanoic acid, respectively,
according to prior literature procedures. Biotin-PE 2.19 was synthesized as
previously described.109 Solution fluorescence studies were performed using a
Perkin Elmer LS55 fluorimeter. For photocleavage, samples were irradiated with
a Rayonet Preparative Type RS photoreactor while suspended in a cuvette
covered with a Pyrex beaker as a filter. Disposable polystyrene cuvettes were
purchased from Fisher scientific. Microplate-based fluorescence measurements
were performed using a BioTek synergy 2 multi-detection microplate reader.
Black reacti-bind streptavidin high binding capacity (HBC) coated 96-well
microplates were purchased from Pierce Biotechnology (Rockford, IL). Cell
images were captured using a Leica SP2 laser scanning confocal microscope.
Fluorescent cell counting was performed using a BD FACS (Fluorescence
Activated Cell Sorting) Calibur flow cytometer.
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tert-Butyl-2-nitro-4-(prop-2-yn-1-ylcarbamoyl)benzylcarbamate (2.2). To 4(((Tert-butoxycarbonyl)amino)methyl)-3-nitrobenzoic acid (2.8) (0.718 g, 2.40
mmol) dissolved in 200 mL of dichloromethane in a 500 mL round-bottomed flask
was added dicyclohexylcarbodiimide (DCC) (0.743, 3.60 mmol), and N,Ndimethylaminopyridine

(DMAP)

(0.147

g,

1.20

mmol,).

After

30

min,

propargylamine (185 µL, 2.88 mmol) was added. The reaction was then allowed
to stir overnight, after which it was washed with water, and the aqueous portion
was extracted with dichloromethane (3 x 25 mL). The organic layers were then
combined and dried with magnesium sulfate, filtered and concentrated by rotary
evaporation. Column chromatography using gradient elution with 30-50% ethyl
acetate-hexanes gave 2.2 as a yellow solid (638 mg, 79% yield). 1H NMR (500
MHz, CD3OD): δ 8.45 (s, 1H), 8.06 (d, J = 3.3 Hz, 1H), 7.63 (d, J = 3.6 Hz, 1H),
4.55 (s, 2H), 4.13 (d, J = 2.5 Hz, 2H), 2.58 (t, J = 2.5 Hz, 1H), 1.41 (s, 9H)).

13

C

NMR (126 MHz, CD3OD): δ 165.46, 156.59, 147.87, 138.06, 134.03, 132.15,
130.23, 124.01, 79.98, 79.05, 77.29, 71.18, 48.54, 41.80, 33.57, 29.29, 28.02,
25.48, 24.79. HRMS-DART [M-H]- calcd for C16H19N3O5, 332.1246; found
332.1243.
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(R)-2,3-dihydroxypropyl-4-methylbenzenesulfonate (2.11). To (S)-(+)-1,2Isopropylideneglycerol (2.10) 1.00 g, 3.49 mmol) dissolved in 50 mL of methanol
in a 500 mL round-bottomed flask was added 125 mL of 0.50 N hydrochloric
acid, and the reaction mixture was allowed to stir for 12h. The excess HCl was
neutralized by adding solid sodium bicarbonate until carbon dioxide gas release
was complete. Next, the crude mixture was passed through celite, filtered off,
and the methanol was removed by rotary evaporation. Compound 2.11 was then
eluted with 100% ethyl acetate using normal phase silica gel column
chromatography and obtained as colorless oil (816 mg, 95% yield). 1H NMR (500
MHz, CDCl3): δ 7.77 (d, J = 7.8 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 4.03 (s, 2H),
3.92 (s, 1H), 3.57 (m, 2H), 2.42 (s, 3H).

13

C NMR (151 MHz, CDCl3): δ 145.22,

132.21, 130.02, 127.95, 70.94, 69.68, 62.77, 21.62. HRMS-DART [M+H]+ calcd
for C10H14O5S, 247.0640, found 247.0644.
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(S)-3-(4-((4-(((tert-butoxycarbonyl)amino)methyl)-3-nitrobenzamido)methyl)1H-1,2,3-triazol-1-yl)propane-1,2-diyl distearate (2.13). To alkyne 2.2 (0.400 g,
1.20 mmol) dissolved in 125 mL tetrahydrofuran-water (1:1) in a 250 mL roundbottomed flask was added azide 2.3 (0.780 g, 1.20 mmol). Next, copper sulfate
pentahydrate (0.390 g, 1.56 mmol) and lastly sodium ascorbate (0.475 g, 2.40
mmol) were added. After overnight stirring, the solution was then concentrated
and

dried

under

high

vacuum.

Column

chromatography

with

5%

methanol/dichloromethane gave product 2.13 as a light yellow solid (575 mg,
50% yield). 1H NMR (500 MHz, 85% CDCl3-CD3OD): δ 9.06 (s, 1H), 8.54 (s, 1H),
8.13 (d, J = 8.5 Hz, 1H), 7.85 (s, 1H), 7.70 (d, J = 5.2 Hz, 1H), 6.54 (s, 1H), 5.49
– 5.37 (m, 1H), 4.71 – 4.58 (m, 4H), 4.38 (dd, J = 12.0, 3.8 Hz, 2H), 4.10 (dd, J =
7.1, 4.8 Hz, 2H), 2.41 – 2.24 (m, 4H), 1.69 – 1.53 (m, 4H), 1.45 (s, 9H), 1.27 (s,
56H), 0.89 (t, J = 6.5 Hz, 6H).

13

C NMR (126 MHz, 85% CDCl3-CD3OD): δ

173.85, 173.20, 165.83, 156.71, 154.58, 148.24, 145.05, 138.24, 134.53, 132.39,
131.00, 124.46, 77.82, 77.56, 69.68, 62.41, 50.48, 49.00, 35.15, 34.23, 33.94,
32.62, 32.16, 31.07, 29.92, 29.72, 29.59, 29.35, 29.25, 28.43, 26.25, 25.84,
25.07, 24.96, 22.90, 14.19. HRMS-DART [M+H]+ calcd for C55H94N6O9, 983.72,
found 983.73. [α]24.0
-3.33°(c 1, CHCl3).
𝐷
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ADIBO−Nitrophenyl−Lipid (2.1). In a 50 mL round-bottom flask, compound 2.13
(42.6 mg, 0.113 mmol) was dissolved in 10 mL dichloromethane/trifluoroacetic
acid (1:1) and stirred for 5 h. Excess acid was removed by rotary evaporation
with

dichloromethane.

The

free

amine

was

re-dissolved

in

15

mL

dichloromethane. To this solution were added hydroxybenzotriazole (HOBt, 15.3
mg, 0.113 mmol) and O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU, 42.8 mg, 0.113 mmol). After 30 min, a mixture
containing ADIBO 2.4 (0.038 g, 0.113 mmol) dissolved in 10 mL dichloromethane
with diisopropylethylamine (92.6 µL, 0.566 mmol) was added to the reaction
mixture, which was then allowed to stir at rt under nitrogen atmosphere
overnight. The next day, the crude mixture was passed through celite and then
washed with 50 mL water. The collected aqueous phase was next washed with
dichloromethane (3 x 20 mL). The organic layers were then combined and dried
with

magnesium

sulfate.

After

filtration
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and

concentration,

column

chromatography was carried out through gradient elution with 7-10% methanoldichloromethane, which provided lipid 2.1 as a yellow-white oily solid (53.44 mg,
38% yield). 1H NMR (500 MHz, 85% CDCl3-CD3OD): δ 8.79 (t, J = 5.7 Hz, 1H),
8.54 (d, J = 1.9 Hz, 1H), 8.05 (d, J = 12.7 Hz, 1H), 7.79 (s, 1H), 7.67 (d, J = 7.6
Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.42 – 7.37 (m, 3H), 7.34 – 7.26 (m, 4H), 6.89 –
6.85 (m, 1H), 5.43 – 5.37 (m, 1H), 5.16 – 5.11 (m, 1H), 4.73 – 4.68 (m, 2H), 4.65
– 4.57 (m, 4H), 4.33 (dd, J = 12.2, 4.2 Hz, 1H), 4.08 (dd, J = 12.2, 5.4 Hz, 1H),
3.37 (dq, J = 4.2, 1.4, 0.9 Hz, 1H), 3.26 – 3.21 (m, 1H), 3.15 (ddd, J = 8.6, 7.5,
0.9 Hz, 2H), 2.36 – 2.28 (m, 5H), 2.05 – 1.98 (m, 1H), 1.58 (dq, J = 32.6, 6.9 Hz,
4H), 1.41 (dd, J = 10.1, 3.7 Hz, 4H), 1.26 (s, 56H), 0.88 (t, J = 6.8 Hz, 6H).

13

C

NMR (151 MHz, 85% CDCl3-CD3OD): δ 173.64, 173.28, 172.97, 172.60, 172.25,
171.95, 165.55, 151.05, 148.17, 147.95, 144.92, 137.24, 134.35, 132.25, 132.13,
130.82, 129.15, 128.84, 128.67, 128.40, 128.06, 127.33, 125.74, 124.33, 124.25,
123.03, 122.59, 114.87, 107.80, 77.35, 69.51, 62.24, 60.77, 55.74, 54.87, 50.35,
49.12, 35.55, 35.08, 34.52, 34.12, 32.05, 31.71, 31.25, 29.83, 29.62, 24.91,
22.80, 14.16. MALDI-MS: [M+Na]+ calcd for
1263.77. [α]24.0
+1.2°(c 1, CHCl3).
𝐷
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C72H104N8O10, 1263.78 ; found

(S)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1Hpyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl 6-azidohexanoate) (2.20). To 6azidohexanoic acid (2.23) (1.13 g,7.20 mmol) dissolved in 30 mL dry
dichloromethane

in

a

500

mL

round-bottomed

flask

was

added

dimethylaminopyridine (DMAP) (0.88 g, 7.20 mmol), N,N′-diisopropylcarbodiimide
(DCC) (1.13 mL, 7.20 mmol) and Scandium(III) triflate (0.71 g, 1.44 mol). The
reaction mixture was cooled to -8 ºC. Lastly, (S)-(+)-Camptothecin (2.22) (0.83 g,
2.38 mmol) was added and the resulting mixture was allowed to stir for 18h. The
reaction mixture was washed with 0.1 N HCl and 1% (v/v) sodium bicarbonate
solution. Residual water was dried over magnesium sulfate and then was passed
through celite and filtered off. Compound 2.20 was then eluted with 100% ethyl
acetate using normal phase silica gel column chromatography and obtained as a
white solid (712 mg, 61% yield). 1H NMR (500 MHz, CDCl3): δ 8.40 (s, 1H), 8.22
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(dd, J = 8.5, 0.8 Hz, 1H), 7.96 – 7.93 (m, 1H), 7.86 – 7.83 (m, 1H), 7.68 (m, J =
8.1, 6.9, 1.2 Hz, 1H), 7.21 (s, 1H), 5.68 (d, J = 17.2 Hz, 1H), 5.41 (d, J = 17.2 Hz,
1H), 5.29 (dd, J = 3.5, 1.2 Hz, 2H), 3.22 (td, J = 6.9, 2.7 Hz, 2H), 2.52 (dt, J =
10.4, 7.3 Hz, 2H), 2.29 (dd, J = 14.0, 7.4 Hz, 1H), 2.18 – 2.13 (m, 1H), 1.72 –
1.67 (m, 2H), 1.60 (ddd, J = 11.1, 5.6, 2.8 Hz, 1H), 1.46 – 1.40 (m, 1H), 1.25 (s,
2H), 0.98 (t, J = 7.5 Hz, 3H).

13

C NMR (151 MHz, CDCl3) δ 172.39, 167.52,

157.33, 152.34, 148.84, 146.21, 131.21, 129.52, 128.45, 128.22, 128.17, 128.04,
120.28, 95.89, 75.82, 67.10, 51.12, 49.91, 33.57, 31.84, 28.49, 26.03, 24.17.
HRMS-DART [M+H]+ calcd for C26H25N5O5, 488.1933, found 488.1935.
Liposome preparation. Stock solutions were made of synthetic lipid 2.1, PC and
biotin lipid 2.19 for microplate studies. Examples of each stock solution used are
as follows: 80.0 mg lipid 2.1, 17.2 mg PC, and 3.90 mg 2.19 were each weighed
into separate vials and dissolved in 500 µL chloroform to form stock solutions of
1.29 mM lipid 2.1, 1.67mM biotin-PE, and 44.7 mM PC. Using these stock
solutions, 55.9 μL lipid 2.1 stock (2%), 5.40 μL biotin-PE stock (1%), and 78.2 μL
PC stock (97%) were combined in a glass vial. For solution-phase fluorimeter
studies, a representative sample included 31.0 μL of lipid 2.1 stock (4%) and
21.5 μL of PC stock (96%), while a control sample contained 22.4 μL of PC stock
(100%). In each case, the chloroform solvent was removed under a stream of
nitrogen and the resulting mixture was placed under vacuum overnight. The dried
lipids were then hydrated by adding 500 μL of HEPES buffer (20 mM HEPES,
150 mM NaCl, pH 7.4), and rotated on a rotary evaporator for 60 min at 40 ºC.
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The liposomes were then subjected to 10 freeze-thaw cycles and extruded (21
times) to obtain uniform size and lamellarity using an extruder containing a 200
nm polycarbonate filter.
Solution phase fluorescence detection of liposome derivatization. A 2.40
mM solution of azido-coumarin 2.18 in dimethylsulfoxide was prepared. 4.00 μL
of this solution were then diluted with 1.88 mL of HEPES buffer (20 mM HEPES,
150 mM NaCl, pH 7.4), placed into a cuvette and sealed with parafilm to
minimize atmospheric exposure. After an initial fluorescence scan (λex = 350 nm;
λem = 461 nm), 120 μL of control liposomal solution (2 mM, 100 % PC) was
added and fluorescence readings were recorded for 45 min. The same procedure
was followed for the study sample, except 120 μL of liposomal solution (2 mM,
96% PC and 4% lipid 2.1) were added, followed by fluorescence scanning over
time.
Microplate fluorescence liposome derivatization studies. A 400 µM solution
of azido-coumarin 2.18 in dimethylsulfoxide was prepared. In a 96-well
streptavidin-coated microplate, 200 μL of wash buffer (0.5X PBS, pH 7.4, 0.56
mM phosphates) was added to each row to be used. The plates were then
shaken for 30 min, after which the wash buffer was removed. Next, 0, 1, 2.5,
5.00, 7.50, 10.0, 15.0, 20.0, and 25.0 μL of liposome solution (2 mM, 97%PC, 2%
lipid 2.1 and 1% 2.19) and 187.5, 198.5, 169.3, 192.3, 188.8, 177.5, 170, 162.5
μL HEPES buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) were added to the
appropriate wells to produce final liposome concentrations of 0, 10, 25, 50, 75,
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100, 150, 200 and 250 μM in separate wells. In addition, 12.5 (control), 0.50,
1.25, 2.50, 3.75, 5.00, 7.50, 10.0, 12.5 μL azido-coumarin 2.18 solution (5
equivalents, 400 μM solution) were added to each well to a total volume of 200
μL. These solutions were incubated, with shaking, for 3h at rt. Following
incubation, the solutions were removed and each well was washed with 3 x 200
μL wash buffer and 200 μL HEPES buffer (20 mM HEPES, 150 mM NaCl, pH
7.4) was then added. Lastly, fluorescence was measured using a microplate
reader with a 360 nm (± 40 nm) excitation filter and 460 nm (± 40 nm) emission
filters.
Saccharomyces cerevisiae cells. A YPD (yeast extract peptone dextrose) agar
plate was inoculated with S. cerevisiae strain 5288 W CT and incubated at 30 oC
for 24h. Next, 5 mL of YPD media were inoculated with a single colony obtained
from the agar plate and incubated on a shaker at 300 rpm at 30 oC with good
aeration for 15h. Next, 500 μL aliquots from this culture were transferred into two
detergent-free 250 mL Erlenmeyer flask containing 25 mL of fresh YPD medium
with (study) and without (control) lipid analog 2.1 (100 μM, 300 μL), both of which
were incubated on a shaker at 300 rpm at 30 oC for 16 to 17h. For good aeration,
the medium constituted of no more than one-fifth of the total flask volume.
Thereafter, the cell concentration was adjusted spectrophotometrically to
approximately 106 CFU/mL. Finally, 1 mL of the cell solution was transferred into
eppendorf tube, centrifuged at 9000 rpm for 4 min, and then stored at –80 oC.
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Fluorescence Imaging and Flow Cytometry Analysis of Fluorescence
Labeling and Photocleavage using Saccharomyces cerevisiae cells. Two 1
mL samples of S. cerevisiae cells, one treated with compound 2.1 (study) and
one untreated (control), were incubated with 100 µM Azide-Fluor 488
dimethylsulfoxide (DMSO) solution overnight at rt. Next, the cell samples were
centrifuged for 3 min at 2500 rpm, the dye solutions were removed, and the cells
were washed once with 5% DMSO in water and twice with 20% DMSO in water,
with vortexing and centrifugation at 2500 rpm for 3 min performed in between
each washing step. Next, 1 mL ice-cold methanol was added to each tube, and
after incubating for 10 min at 0 oC, the sample was centrifuged. Next, 1 mL of
Phosphate Buffered Saline solution (PBS, pH 7.4, 1.19 mM phosphates) was
used to wash the fixed cell samples, which were then centrifuged at 2500 rpm for
3 min. Cells were then subjected to fluorescence microscopy. To assess
photocleavage, 200 µL of clicked cell sample were added into a disposable
cuvette and 800 μL HEPES buffer (20 mM HEPES, 150 mM NaCl, pH 7.4), were
added. For photocleavage, cells were irradiated with 350 nm light while
suspended and covered by Pyrex beakers between four 350 nm bulbs in a
Rayonet Preparative Type RS photoreactor. This was done for different time
periods (1, 2, 3, 4 and 12h) to assess photocleavage over time. After
photoirradiation, the cell samples in buffer were transferred into eppendorf tubes
and centrifuged at 2500 rpm for 3 min, and then washed 7 times with 1 mL of 20
% DMSO/water. Each time they were vortexed and centrifuged at 9000 rpm for 4
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min. Lastly, the cells were washed with 1 mL of 1X PBS buffer (pH 7.4, 1.19 mM
phosphate buffer), and fluorescence microscope images after photocleavage
were then obtained. For flow cytometry analysis, cell samples were analyzed
using a BD FACS (Fluorescence Activated Cell Sorting) Calibur flow cytometer
(Becton, Dickinson and Company, New Jersey, US) equipped with two lasers
(488 nm and 635 nm). Green fluorescence (FL-1) was measured for all cell
samples. Populations of the yeast cells were identified and gated according to
the fluorescent intensity. Data acquisition was performed and analyzed using
FlowJo software. For each sample analyzed in the flow cytometer, at least
10,000 events were acquired.
Cell proliferation assay (MTS). HeLa cells were cultured in a humidified
incubator under 5% CO2 in DMEM medium (Invitrogen) supplemented with 10%
of Fetal Bovine Serum (Invitrogen). The cell viability was measured using the
CellTiter 96 ®Aqueous One Solution (Promega) according to the manufacturer’s
protocol. Briefly, cells were seeded (104 cells per well) 2 days prior to the
experiments to a 96 well plate, and exposed to vehicle (DMSO and liposomes),
CPT, CPT-N3 or CPT-N3 + Liposomes mix at different concentrations of CPT,
CPT-N3 (10 µM, 25 µM and 50 µM) and incubated for 48h. The liposomal
solution consisted of 50 µM lipid analog 2.1 formed as 8.5 mM liposomes (94%
PC, 6% lipid analog 2.1). The MTS assay was performed in 100 µL of DMEM
phenol red free medium (Invitrogen) in each well and 20 µL of the CellTiter
solution was added to the samples, after which the plate was placed in a 37 ⁰C
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incubator with 5% CO2 until it reached the desired color. The absorbance at 490
nm was measured in a plate reader (Synergy 2, Biotek). The results are
representative of 3 independent experiments, performed in quadruplicate. The
inhibition of cell proliferation was expressed as the percentage of vehicle control
(0.01% DMSO in the culture medium for CPT).

Linear alkyne lipid (2.25). In a 50 mL round-bottom flask, compound 2.13 (42.6
mg, 0.113 mmol) was dissolved in 10 mL dichloromethane/trifluoroacetic acid
(1:1) and stirred for 5h. Excess acid was removed by rotary evaporation with
dichloromethane. The free amine was re-dissolved in 15 mL dichloromethane. To
this solution were added hydroxybenzotriazole (HOBt, 15.5 mg, 0.113 mmol) and
O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexa-fluorophosphate (HBTU,
43.2 mg, 0.113 mmol). After 30 min, a mixture containing 2.24 (0.015 g, 0. 113
mmol) dissolved in 10 mL dichloromethane with diisopropylethylamine (95.6 µL,
0.571 mmol) was added to the reaction mixture, which was then allowed to stir at
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rt under nitrogen atmosphere overnight. The next day, the crude mixture was
passed through celite and then washed with 50 mL water. The collected aqueous
phase was next washed with dichloromethane (3 x 20 mL). The organic layers
were then combined and dried with magnesium sulfate. After filtration and
concentration, column chromatography was carried out through gradient elution
with 7-10% methanol-dichloromethane, which provided lipid 2.25 as a yellowwhite oily solid (15.45 mg, 28% yield). 1H NMR (500 MHz, 85% CDCl3-CD3OD):
δ 8.92 (t, J = 5.7 Hz, 1H), 8.60 (d, J = 1.94 Hz, 1H), 8.12 (d, J = 12.89 Hz, 1H),
7.80 (s, 1H), 7.61 (d, J = 7.6 Hz, 1H), 5.41-5.39 (m, 1H), 4.84 (s, 2H), 4.66 – 4.57
(m, 5H), 4.33 (dd, J = 12.2, 5.4 Hz, 1H), 4.08 (dd, J = 11.7, 4.3 Hz, 1H), 3.36 (dq,
J = 4.2, 1.4, 0.9 Hz, 2H), 2.35 (t, J = 7.6 Hz, 2H), 2.30 (t, J = 7.6 Hz, 2H), 1.59
(m, 4H), 1.26 (s, 56H), 0.88 (t, J = 6.8 Hz, 6H).

13

C NMR (151 MHz, 85% CDCl3-

CD3OD): δ 174.05, 173.14, 165.58, 148.50, 144.94, 135.45, 135.06, 132.47,
130.78, 124.76, 69.75, 62.47, 50.52, 41.15, 34.27, 32.20, 29.96, 29.75, 29.62,
29.52, 29.39, 29.29, 25.12, 25.01, 22.93, 14.20.
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2.11 List of Spectra

Spectra 2.1: 1H NMR and 13C NMR of compound 2.2. tert-Butyl-2-nitro-4(prop-2-yn-1-ylcarbamoyl)benzylcarbamate.
63

Spectrum 2.2: Mass Spectrum of compound 2.2. tert-Butyl-2-nitro-4-(prop2-yn-1-ylcarbamoyl)benzylcarbamate.
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Spectra 2.3:

1

H NMR and

13

C NMR of compound 2.11. (R)-2,3-

dihydroxypropyl-4-methylbenzenesulfonate.
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Spectrum 2.4: Mass Spectrum of compound 2.11. (R)-2,3-dihydroxypropyl4-methylbenzenesulfonate.
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Spectra 2.5: 1H NMR and 13C NMR of compound 2.13. (S)-3-(4-((4-(((tertbutoxycarbonyl)amino)methyl)-3-nitrobenzamido)methyl)-1H-1,2,3-triazol-1yl)propane-1,2-diyl distearate.
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Spectra 2.6: 1H NMR and 13C NMR of compound 2.1.
ADIBO−Nitrophenyl−Lipid.
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Spectrum 2.7: Mass Spectrum of compound 2.1.
ADIBO−Nitrophenyl−Lipid.
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Spectra 2.8: 1H NMR and 13C NMR of compound 2.20. (S)-4-ethyl-3,14-dioxo3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl 6azidohexanoate).
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Spectrum 2.9: Mass Spectrum of compound 2.20. (S)-4-ethyl-3,14-dioxo3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl 6azidohexanoate).
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Spectrum 3.0: Mass spectrum of released fluorophore 2.17 following
treatment of S. cerevisiae cells with lipid 2.1, fluorophore 2.14 and
photocleavage.
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Spectrum 3.1: Mass spectrum of camptothecin-lipid conjugate
formed following the incubation of lipid 2.1 with CPT-N3 2.20.
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Spectrum 3.2: Mass spectrum of released camptothecin obtained
following acidic extraction of Hela cells that were treated with
camptothecin-lipid conjugate 2.21.
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Spectrum 3.3: Mass spectrum obtained from a standard solution of
camptothecin subjected to acidic extraction.
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Spectra 3.4: 1H NMR and 13C NMR of compound 2.25. Linear alkyne lipid.

76

CHAPTER THREE
METABOLIC LABELING OF PHOSPHATIDYLSERINE LIPIDS IN
CELLS USING CLICKABLE SERINE ANALOGS FOR TARGETED
LIPOSOME DELIVERY
This chapter shows data which is currently being prepared for submission
to a journal paper by the following authors.
Shahrina Alam, Tanei J. Ricks, Daiane S. Alves, Chelsi D. Cassilly, Abigail
T. Farmer, Kathrin K. Tscherch, Nicholas M. Wadsworth, Shawn R.
Campagna, Todd B. Reynolds, Francisco N. Barrera, and Michael D. Best.
3.1 Importance of PS in Cell Membranes
In addition to acting as the primary components of cell membranes, lipids and
proteins play important roles in cell–cell-signaling that are of extensive interest.
Furthermore, lipids control many critical biological pathways, and thus aberrant
lipid biosynthesis and activity commonly correlate with diseases including
cancer.118-121 For example, phosphatidylserine (PS) is an important biomarker
that participates in diverse biological processes. PS acts as a ligand for a number
of proteins, thereby directing membrane association of these proteins through
non-covalent proteinlipid binding interactions.122 One particularly well studied
example is Annexin A5,123 a protein that participates in PS membrane
translocation

and

is

involved

in

key

antiphospholipid antibody syndrome,126,
imaging applications.128
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127

anti-coagulation

events,124,

125

and has been used for cancer

While changes in lipid composition of cell membranes during carcinogenesis
have been heavily explored, very little insight has been acquired. Nevertheless,
in recent years lipidomics in cancer research has gained more attention. For
example, the outer leaflets of eukaryotic plasma membranes are chiefly
composed of neutral phospholipids, such as phosphatidylcholine (PC) and
sphingomyelin (SM). On the other hand, negatively charged phospholipids
including phosphatidylserine (PS) as well as phosphatidic acid (PA) are normally
found in the inner leaflet.129 Interestingly, during apoptosis and the onset of
certain cancers, PS is translocated to the outer leaflet of the cell membrane. This
may be due to the reduced activity of phospholipid translocase enzymes may
perturb this asymmetry. The function of ATP dependent phospholipid translocase
is to transport PS and PE between bilayer leaflets and has been found to be
vulnerable to oxidative injury. Another possible reason might be the activation of
a scramblase triggered by increased intracellular Ca2+ levels, which leads to nonspecific movement of phospholipids.130 Thus, loss of asymmetry causes
distribution of the negatively charged PS on the external surface of cancerous
and other pathological cells131 as well as apoptotic cells.132
As a result of this phenomenon, PS represents a powerful target for drug
delivery and biomarker for identifying cancer cells. In spite of the crucial role of
lipids such as PS in metabolic activities, it is still a major challenge to follow the
biosynthesis of these metabolites at their sites of origin, essentially due to the
complexity of lipid biosynthetic pathways, in which numerous molecules are
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continually undergoing interconversion within the complex environment of cellular
membranes. In this project, we describe the development of clickable serine
analogs that can be used to produce tagged versions of PS in cells. This is
envisioned as a powerful tool for tracking the biosynthesis and trafficking of PS in
cells. Furthermore, due to the presentation of PS on the outer surfaces of cancer
cells, an additional goal is to exploit this tag as a handle for selective drug
delivery to labeled cells.
3.2 Biosynthetic Route to Track Incorporation of Precursor Molecules
Complex processes including lipid biosynthesis and vesicle- and proteinmediated transfer regulate the composition and subcellular localization of
signaling lipids, and defects in any of these processes typically result in
disease.133-138 Several routes are well known for the biosynthesis of PS,
essentially depending on the nature of organism, although many of these
processes exploit serine as a substrate for an exchange reaction with a lipid
(Figure 3.1). For example, prokaryotes commonly convert cytidine diphosphatediacylglycerol (CDP-DAG) and serine to PS, while mammalian cells (Figure 3.2)
instead utilize a transphosphatidylation reaction with phosphatidylcholine (PC) or
phosphatidylethanolamine (PE).The biosynthetic route below shows a partial
yeast phospholipid production starting form glycerol 3-phosphate (G3P), which is
biocatalyzed by acyl-coenzyme A (Acyl-CoA) and forms lyso-phosphatidic acid
(LPA) and then phosphatidic acid (PA) in two consecutive reactions. 139 In the
next phase, PA is dephosphorylated to diacylglycerol (DAG) or converted to
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cytidine diphosphate- (CDP-) DAG, which readily transforms into PS through
reaction with serine. Deacylation of PS results in lyso-phosphatidylserine (LPS).
Alternatively,

decarboxylation

of

PS

may

occur

to

generate

phosphatidylethanolamine (PE). PE can then undergo three methylations,
progressing

through

monomethylphosphatidylethanolamine

dimethylphosphatidylethanolamine

(DMPE)

to

(MMPE)

ultimately

and
form

phosphatidylcholine (PC). Alternatively, PE and PC can be converted back to PA,
and DAG can instead be converted to PE and PC through reaction with CDPethanolamine (CDP-ETA) and CDP-choline, respectively.

Figure 3.1: Lipid biosynthetic pathway in Saccharomyces cerevisiae
showing production of different phospholipids and their interconversions.
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Figure 3.2: Lipid biosynthetic pathway for mammalian cells showing
various phospholipids generation from glycerol-3 phosphate.

3.3 Objectives of Labeling Phospholipids
Metabolic labeling studies are immensely useful as they enable the dynamic
detection and characterization of complex biomolecules in cells. Dramatic
advancements in labeling have been achieved by introducing diminutive clickable
tags onto substrates, providing analogs that successfully infiltrate biosynthetic
pathways and generate functionalized products in cells. 11,

12

Prior work on

labeling studies has demonstrated the labeling of complex cell-surface glycans
using sugar precursor analogs bearing clickable tags.11,

25, 27, 35, 140

Later,

researchers become more interested in labeling lipid analogs as well through a
similar approach. For example, tagged fatty acids have been extensively
exploited to study posttranslational lipidation.141 Phospholipids including PC142-144
and glycophosphatidylinositol (GPI) anchors145 have been studied by labeling
with tagged choline and inositol analogs, respectively. In 2009 Salic et al.
81

described a protocol where they demonstrated incorporation of labeled choline
precursors into PC.142 Next, chemical derivatization was achieved, followed by
microscopic visualization to confirm the labeling.
The present study uses this strategy to biosynthetically label and
microscopically image phospholipids within cellular membranes, and particularly
PS. As has already been mentioned, since PS is a promising targeting group as
a biomarker, our aim is to perform the metabolic labeling of PS and other lipids
using clickable serine analogs to enhance the ability to track the biosynthesis and
localization of PS. Additionally, our labeling study will enable the localization of
clickable tags on the outer surfaces of cells undergoing apoptosis and those
associated with certain cancers, and thus can provide a handle for delivery and
imaging applications.
3.4 Design of Serine Analogs for Metabolic Labeling of PS
In a first step towards these goals, we designed and synthesized serine
precursors, one with an azido group and another with an alkyne tag, both for click
chemistry derivatization, attached at the amino group of serine (Scheme 3.1).
This was designed to achieve the metabolic incorporation of these probes to
produce labeled PS products through reaction with CDP-DAG, as shown in
biosynthetic pathway (Figure 3.1). For detection of labeled products, we utilized
the strain promoted azide-alkyne cycloaddition reaction (SPAAC) to click on a
fluorophore, which enabled visualization using confocal microscopy. In addition,
mass spectrometry studies were run to detect labeled lipid products from cells in
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collaboration with Abigail T. Farmer, a graduate student in the lab of Dr. Shawn
Campagna in the Chemistry Department at the University of Tennessee using an
Orbitrap Exactive MSs and/or a TSQ Quantum Triple Quadrupole MS

3.1-3.2

3.6

Scheme 3.1: Strategy for analyzing metabolic labeling of lipids using serine
analogs 3.1-3.2 in eukaryotic cells through fluorescence microscopy and
mass spectrometry.

3.5 Synthesis of Precursor Serine Analogs
We first designed the reporter-tagged serine analogs, which would be the
most suitable and efficient for PS production with minimal modifications. In PS,
the head group is attached via the side chain hydroxyl group of serine, and thus
either the carboxyl or amine moiety could be utilized for the introduction of
clickable tags. Initially, we selected the amine group for modification to preserve
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the natural charge of PS. Moreover, modification of the amino group is also
beneficial since it discourages the incorporation of serine analog into protein
biosynthesis.
Compounds 3.1 and 3.2, containing either a propargyl or azidopropyl moiety
attached at nitrogen, were synthesized from O-tert-butyl-L-serine tert-butyl ester
3.3 as shown in Scheme 3.1. This was performed through alkylation of protected
serine 3.3 with either a propargyl group to 3.4 or azidopropyl moiety to 3.5,
followed by deprotection to 3.1-3.2, respectively.

Scheme 3.2: Synthesis of serine analogs in two steps.
In the first step, the desired tag (propargyl or propylazido) was installed at
onto the amino group, which was followed by deprotection to obtain
compounds 3.1 and 3.2.

3.6 Effect of Probes on Growth Curve
We initially set out to determine whether probes had a deleterious effect on
cell growth. In doing so, we first pursued the growth curve with yeast cells. S.
cerevisiae cells possess significant similarities in terms of the genes, enzymes
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and pathways associated with lipid metabolism in mammalian cells, 146 and
moreover this system was selected for convenient access to an abundance of
cells. Therefore, we considered S. cerevisiae cells as our model eukaryotic cells
for growth curve and mass spectrometry studies. Cells were grown in the
presence or absence of azide-tagged serine probe 3.2 (1.5 mM) and standard
procedures were used to track optical density over time during cell culture. As
can be seen in Figure 3.3, the two resulting growth curves were virtually
indistinguishable, indicating that probe 3.2 does not cause cell toxicity. Both
growth curves consist of comparable lag phase, log phase and stationary phase.
The cell growth in both cases was exponentially accelerating for the first 24 hours
and then reached persistent OD600 values, indicating the population remained
constant in the stationary phase.

4

Control cells (- 2)

3.5

Study cells (+ 2)

OD (600 nm)

3
2.5
2

1.5
1
0.5
0
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16 20 24 28 30 32 36 40 44 48
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Figure 3.3: Growth curves of yeast cells in the presence (study) or absence
(control) of 1.5 mM of serine azide probe 3.2.
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3.7 Mass Spectrometry Results
Our next experiment was designed to assess the efficacy of these probes for
the infiltration of biosynthetic pathways in live cells to produce labeled lipid
products (Scheme 3.1A). For this, we performed mass spectrometry-based
lipidomics to detect lipid products bearing the added clickable handle. Cells were
grown in the presence and absence of tagged serine analogs, lysed, and then
subjected to LC-MS/MS to detect labeled products. In studies with alkynyl probe
3.1, we have detected labeled products corresponding to PS, LPS, and PC
(Table 3.1, experimental section). Based on the Figure 3.1 phospholipid
chemical transformations, all these lipid products are highly reasonable to include
the added click tag. Probe 3.2 delivered similar results as azide-tagged products
corresponding to PS, PE, DMPE, PC, and LPS were detected (Table 3.2,
experimental section). These results provide evidence that serine probes 3.1-2
are effective as substrates for conversion to PS, after which they can be further
decarboxylated to PE derivatives and then undergo methylation to PC structures,
passing through DMPE intermediates. PS products can also undergo hydrolysis
to LPS. Importantly, these data validate that incorporation of the clickable tags at
nitrogen does not deter the normal entry into multiple lipid biosynthetic pathways.
However, it should be noted that for mass spectrometry results with 3.2, we also
detected peaks corresponding to labeled lipids in one of the two controls, which
is concerning potential issue. At this point, we are trying to rerun this experiment.
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Additionally, in studies using probe 3.1, we observed low levels of endogenous
lipids in the controls, which we are currently investigating as well.
In addition to yeast, we have attempted different cell lines to acquire mass
spectrometry data for labeled phospholipids. For example, T24 (human bladder
cancer cell) and cho1 mutant yeast cell lines were run to detect labeled
phospholipids. The cho1 mutant cell line lacks the PS synthase enzyme, and
thus is unable to convert serine analogs into labeled phospholipids, and can be
considered as negative control. The T24 cell line was pursued to perform studies
in human cells, but we didn’t see any labeled species and the cho1 mutant didn’t
show us any difference from wild type yeast cells. One of the reasons might be
the extraction procedure we used for cell lysis and extraction of lipids. Here, we
used hydrochloric acid (0.1N in methanol) for lipid extraction from membranes
which might cause hydrolysis of lipid head group. To solve this problem, we
modified our lipid extraction procedure, ultimately using a modification of Bligh
and Dyer method.147 Moreover, different concentrations of probes have been
used in metabolic labeling of phospholipids in live cells. It has been found that
the mean concentration of serine in yeast cells is around 1.2 mM and the same
concentration for probe 3.2 was applied for growing yeast cells.148
3.8 Fluorescence Imaging of Lipid Labeling in Cells
The next experiment we performed utilized fluorescence microscopy to exploit
the clickable tags of labeled phospholipids and click chemistry to visualize the
localization of labeled lipids in cells (Scheme 3.1B). For this study, we chose N87

azidopropyl serine probe 3.2, which allowed for labeling through SPAAC (copperfree click chemistry) using dibenzocyclooctyne-Cy3 (DBCO-Cy3) reagent 3.6.
These studies were performed using larger mammalian cells, specifically T24
bladder cancer cells, to enhance the size and resolution of images. In this
experiment, T24 cells were incubated with and without the probe 3.2 (100 µM)
overnight. Next, they were washed with PBS++ buffer and incubated with 3.6 (1
µM) for one hour. After incubation, the cells were again washed with PBS++ buffer
to remove unbound dye from the cell culture. Using 4% paraformaldehyde and
ProLong Diamond Antifade Mountant with DAPI the cells were fixed and stained.
After drying, the coverslips bearing the cells were sealed and subjected to
fluorescence microscopy. The results revealed that cells treated with probe 3.2
provided a strong fluorescence signal (Figure 3.4A), while untreated cells
yielded minimal background (Figure 3.4C). Furthermore, the fluorescence was
primarily localized at membrane portions within the cells, which supports the
incorporation of the label into lipid products. These results further validate the
labeling of lipid products and demonstrate the ability to derivatize resulting
compounds with fluorophores for their detection via microscopy.
3.9 Fluorescence Imaging of Liposome Targeting of PS in Cells
After performing successful experiments using fluorescence labeling and
microscopy, we designed an experiment to exploit the lipids labeled with
clickable tags to demonstrate delivery based on the presence of click tag towards
eventual selective drug delivery.
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Figure 3.4: Fluorescence microscopy images of tagged products resulting
from azido-serine probe in human T24 cells.
A. Representative fluorescent image showing that cells treated with 3.2
show significant fluorescence attributed to the labeling of lipid products. B.
Bright field image of treated cells. C. Control cells not treated with 3.2 show
minimal fluorescence. D. Bright field image of control. Scale bar equals 50
µm.
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As has already been mentioned, due to the translocation of PS to membrane
outer leaflets driven by apoptosis, PS presence on cell surfaces could provide a
marker for the targeting of certain cancers. Scheme 3.3 depicts our initial
strategy for evaluating the prospects of this delivery system by targeting
liposomes containing cyclooctyne-lipid 3.7 to cells bearing labeled PS. This was
initially investigated through the delivery of fluorescent markers by incorporating
commercially available fluorescent lipids into the delivery liposomes. First,
compound 3.2 was fed to T24 cells for conversion into tagged lipids. These cells
were cultured at Barrera’s lab, and the cell growth in presence of probe was
performed by Daiane S. Alves and Nicholas M. Wadsworth, an undergraduate
student working for Dr. Francisco Barrera. Next, the cell samples were washed
with the PBS++ buffer (supplemented with 1 mM MgCl2 and 100 µM CaCl2).
Study samples were then incubated with liposomes primarily composed of PC
(89.9%) as the bulk lipid along with DSPE-PEG(2000)-DBCO (3.7, 5%) for
selective reaction with the azide tag of 3.2 via SPAAC (Scheme 3.3).
Additionally, PEG(2000)-PE amine (5%) was included, which is commonly used
to shield liposomes from decomposition during drug delivery applications.149
Finally, rhodamine-labeled PE (0.08%) was included to enable detection of
liposome localization through fluorescence microscopy. In control liposomes, 3.7
was excluded and replaced with additional PC. After washes with PBS++ buffer
(supplemented with 1 mM MgCl2 and 100 µM CaCl2), fluorescence microscopy
experiments were performed.
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Scheme 3.3: Cartoon description of targeted delivery of fluorescent
liposomes to cells through SPAAC driven by the presence of clickable
lipids on the cell surface.

Representative microscopy data show that treatment of cells with probe 3.2
and liposomes containing 3.7 led to significant delivery of fluorescent lipids to
cells (Figure 3.5A), which did not occur when the same labeled cells were
treated with liposomes lacking 3.7 (Figure 3.5C). We have attempted this
experiment with various liposomes compositions such as the exclusion of
PEG(2000)-PE and using 2% Rhodamine PE. The best results we acquired
when we incorporated 5% PEG(2000)-PE and 0.08% rhodamine PE in
liposomes. We also tried different incubation times, 6, 16 and 24 hours, of which
16 hours appeared to provide the optimal results.
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Figure 3.5: Fluorescence microscopy images of tagged products resulting
from azido-serine probe in human cells through labeling with fluorescent
reagent.
A. Representative fluorescent image shows that cells treated with 3.2 and
fluorescent liposomes containing 3.7 yield signal B. DAPI nuclear stain in
the second channel of treated cells. C. Control cells treated with 3.2 and
liposomes lacking 3.7 show diminished fluorescence. D. DAPI nuclear
staining of control. Scale bar corresponds to 25 µm.
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3.10 Imaging Studies with Other Serine Probes
Another serine analog, C-alkynyl-serine probe 3.8, was synthesized for the
labeling and mass spectrometry experiments. The synthesis of 3.8 (Scheme 3.4)
began with 3.9 that has free hydroxyl and carboylic acid groups. In the first step,
the hydroxyl group was protected as a tetrahydropyran (THP) group, and next
the propargyl group was installed via peptide coupling reaction conditions.
Finally, the boc and THP groups were deprotected using TFA in DCM.

Scheme 3.4: Synthesis of C-alkynyl probe 3.8 from Boc-protected L-serine.

For fluorescence labeling and imaging studies with this serine probe, we
employed copper catalyzed click chemistry using azide-Fluor 488 (2.14)
alongside probe 3.2. For this, we grew yeast cells with and without compounds
3.2 and 3.8 (100 micromolar) individually. Next, cells were washed with PBS
buffer, and treated with azide-Fluor 488 (2.14) (10 micromolar) and lastly,
samples were washed three times with 20% DMSO-water solution.
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Figure 3.6: Fluorescence images for S. cerevisiae cells with N-alkynyl and
C-alkynyl serine probes. A, B and C are images for cells grown without any
probe compound, and in the presence of 3.1 and 3.8, respectively. D, E and
F are bright field images of the corresponding samples.
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As Figure 3.6 indicates, the control that has no probe (neither 3.1 nor 3.8)
does not show much fluorescence, whereas the other two study samples yield
significant fluorescent in yeast cells. While fluorescence image for the study
(treated with 3.8) is significantly greater than the control (not treated with 3.8),
the fluorescne does not appear to be localized across membranes within the
cells. Moreover, with C alkynyl probe 3.8, we didn’t detect a number of
phospholipids on mass spectrometry because the tag on the C-terminus limits its
conversion from PS into other phospholipids. However, this could be a positive
for achieving specificity for the labeling of PS in cells.
3.11 Tagged Analogs of LPA and LPS for Lipid Labeling
An alternate strategy we have begun pursuing for the labeling of lipids
involves the use of tagged lyso-lipids. As previously discussed, lipids including
LPA and LPS act as substrates that are converted to the important phopholipids
PA and PS, respectively, through acylation. We have designed labeled LPA
(3.21) and LPS (3.24) probes that contain an azido tag appended at the end of
the lipid tail to further separate the label from the lipid head group, which is the
primary site for lipid modification and recognition. The azido-tail is attached by an
ether linkage to avoid release of the clickable label by acyl chain hydrolysis.
Initial synthetic progress towards these probes is shown in Scheme 3.5. This
route starts with the protection of a (S)-glycerol acetonide (2.9) with a pmethoxybenzyl (PMB) group and then the acetonide ring was deprotected using
acid to 3.13. Next, alkylation with 1, 11-dibromoundecane in the presence of
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butyl tin(II) oxide- was used to obtain 3.14, after which the deprotection of the
PMB group using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in DCM-H2O
(18:2) would give us 3.15. Different ratio of DCM-H2O solutions were tried that
resulted in very poor yield of 3.15. Once synthesized, compound 3.15 could be
converted into 3.16 by treatment with sodium azide in DMF.

Scheme 3.5: Synthesis of azide tagged tail for LPA and LPS.

We next pursued an alternate route, shown in Scheme 3.6, using S-glycidol
(3.17) as the starting material. This was treated with borontrifluoridediethyletherate in the presence of 11-bromo-1-undecanol (3.18) to produce 3.15.
Next, bromo group was replaced with azido group using sodium azide, followed
by a phosphorus coupling reaction with diethyl chlorophosphate (3.19) in the
presence of tetramethyl piperidine (TMP) to obtain 3.20. Finally, deprotection
with trimethylsilylbromide (TMSBr) in DCM and methanol gave us LPA 3.21.
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Scheme 3.6: Synthesis of LPA with an azide tagged acyl tail.
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Scheme 3.7: Synthesis of LPS with an azide tagged acyl tail.

LPS probe 3.24 could also be accessed using 3.16 as shown in Scheme 3.7.
This can be reacted with ethyl dichlorophosphate in the presence of TMP,
followed by a second coupling reaction with protected serine 3.22 in the
presence of TMP to provide 3.23. Deprotection of the Boc and ethyl groups can
be carried out by treatment with TFA and TMSBr in DCM, respectively, to
produce 3.24.
3.12 Conclusion
We demonstrated that serine analogs with click tags can be incorporated in
eukaryotic and prokaryotic cells, which was validated by fluorescence imaging
and mass spectrometry. The fluorescence imaging results show labeling only in
the presence of tagged serine probes, while the mass spectrometry results
indicate promising peaks for labeled phospholipids that are being followed with
further controls. The labeled PS has also been utilized as a handle for liposomal
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delivery, which has been validated by the delivery of fluorescence-tagged
clickable liposomes. Future studies will involve the synthesis of LPS and
incorporation of LPA and LPS as an alternate avenue for PS labeling. Since the
two compounds have click tags at the end of the acyl tail, this reporter group will
remain unperturbed when these probes undergo metabolic interconversions to
other phospholipids, and could therefore be useful for labeling additional
compounds. We will additionally further study serine probe 3.8 in which the click
tag is introduced as an amide in place of the carboxylic acid as a means for
avoiding decarboxylation in the labeling of PE and downstream lipids. The
trafficking of lipids into different cellular components can be tracked down using
mutant cell lines. For instance, the trafficking of PS to mitochondria for
decarboxylation could be studied using a psd1∆ mutant, which lacks the
mitochondrial PS decarboxylase. We can further analyze the trafficking of PS to
endosomes by blocking PS to PE synthesis with the psd2∆ mutant. We can
additionally analyze PE localization using pem1∆ pem2∆ mutants to block
methylation.
3.13 Experimental
Reagents and solvents were generally purchased from Acros, Aldrich or
Fisher Scientific and used as received. L-α-Phosphatidylcholine (mixed isomers
from

chicken

egg),

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-

[dibenzocyclooctyl(polyethylene
PEG(2000)-DBCO),

glycol)-2000]

(ammonium

salt),

(DSPE-

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N99

[amino(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG(2000) amine),
and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B
sulfonyl) (Rhodamine-PE) were purchased from Avanti Polar Lipids, Inc. O-tertButyl-L-serine tert-butyl ester hydrochloride (3.3), propargyl bromide, and 1,3dibromopropane were purchased from Fisher Scientific. Dibenzocyclooctynecyanine 3(DBCO-Cy3) was obtained from Sigma Aldrich. (S)-(-)-glycidol, diethyl
chlorophosphate, ethyl dichlorophosphate N-(tert-butoxycarbonyl)-L-serine were
purchased from Fisher Scientific. SiliaPrep C18 (17%, 2g, 6mL, 40-63um) was
provided by SiliCycle Inc. Dry solvents were obtained from a Pure solvent
delivery

system

purchased

from

Innovative

Technology,

Inc.

Column

chromatography was performed using 230-400 mesh silica gel purchased from
Sorbent Technologies. NMR spectra were obtained using Varian Mercury 500
and 600 spectrometers. Mass spectra were obtained with JEOL DART-AccuTOF
mass spectrometer with high-resolution capabilities spectrometer. Liposome
extruder and polycarbonate membranes were obtained from Avestin (Ottawa,
Canada). Ultrapure water was purified via a Millipore water system (≥ 18 MΩ·cm
triple water purification system). Solution fluorescence studies were performed
using a Perkin Elmer LS55 fluorimeter. Cell images were captured using a Leica
SP8 White Light Laser Confocal microscope system using a 63x 1.4na oil
objective.
Liposome preparation. Stock solutions were made of rhodamine-PE, DSPEPEG(2000)-DBCO (3.7), DSPE-PEG(2000) amine, and PC to make liposomes.
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Examples of each stock solution used are as follows: 1.0 mg rhodamine-PE, 50.1
mg PC, 5.0 mg DSPE-PEG(2000)-DBCO (3.7) and 2.5 mg DSPE-PEG(2000)
amine were each weighed into separate vials and dissolved in 1000 µL
chloroform to form stock solutions of 0.76 mM rhodamine-PE, 65.05 mM PC,
1.62 mM DSPE-PEG(2000)-DBCO (3.7) and 0.89 mM DSPE-PEG(2000) amine.
Using these stock solutions, 1.80 μL rhodamine-PE stock (0.08%), 54.0 μL
DSPE-PEG(2000)-DBCO (3.7, 5%), 98.2 μL DSPE-PEG(2000) amine stock
(5%), and 24.2 μL PC stock (89%), were combined in a glass vial. For control
liposomes, 1.80 μL rhodamine-PE stock (0.08%), 98.2 μL DSPE-PEG(2000)
amine stock (5%), and 25.5 μL of PC stock (94.9%) were combined in a second
vial.

In each case, the chloroform solvent was removed under a stream of

nitrogen and the resulting mixture were placed under vacuum overnight. The
dried lipids were then hydrated by adding 350 μL of Milli-Q water, and rotated on
a rotary evaporator for 60 min at 60 ºC. The liposomes were then subjected to 10
freeze-thaw cycles and extruded (21 times) to uniform size and lamellarity using
an extruder containing a 200 nm polycarbonate filter.
Fluorescence imaging of lipid labeling in cells and delivery of liposomes.
T24 cells (transitional cell bladder carcinoma, ATCC® HTB-4™) were cultured in a
humidified incubator at 37°C under 5% CO2 in McCoy medium (Invitrogen)
supplemented with 10% of fetal bovine serum (Invitrogen). Briefly, cells were
seeded (105 cells per well) in a 12-well plate 2 days prior to the experiments to
cover slips, treated with or without 1 mM of 3.2, and incubated for 16h in Opti101

MEM medium (Invitrogen). Cells were next washed with PBS ++ buffer
(supplemented with 1 mM MgCl2 and 100 µM CaCl2). For experiments involving
the fluorescence labeling of lipids (Figure 1), cells grown in the presence or
absence of 3.2. were next incubated for 1 h with 98 µL of a 1.02 mM stock of
DBCO-Cy3 dye 3.6 in a total volume of 1 mL of PBS++. For liposome delivery
studies, all cells were grown with 3.2, after which they were treated for 1h with
liposomes (5 mM) either containing or lacking 3.7 prepared as described in the
previous section. Finally, cells were washed four times with PBS++, fixed for 30
min in 4% paraformaldehyde and mounted with ProLong Diamond Antifade
Mountant with DAPI (Invitrogen) or Vectashield Antifade Mounting Medium
(Vector Laboratories). Cells were visualized employing a Leica SP8 White Light
Laser Confocal microscope. Contrast and brightness settings were selected so
that all pixels were in the linear range. Images are the product of fourfold line
averaging.
Yeast cell growth and mass spectrometry procedures
Saccharomyces cerevisiae cell growth. S. cerevisiae TRY 181 (wild-type,
uraΔhisΔ) strained cells was streaked or spread on YPD (1% yeast extract, 2%
peptone, 2% dextrose, 2% agar) plates from inoculum and incubated at 30 oC,
and single colonies were seen after ∼24h. Next, from a single colony, a loop of
cells was added to 5 mL 2% galactose minimal medium (with galactose as a
carbon source) into a glass cell culture tube and incubated at 30 oC at 225 rpm
with good aeration overnight to an OD600 (optical density) of 2.33. Next, 214.6102

μL aliquots from this culture were transferred into two detergent-free glass cell
culture tubes containing 4.78 mL of fresh 2% galactose medium with and without
N-propylazide serine analog 3.2 (300 μL of a 25 mM solution), both of which
were incubated for 16 to 17 h until the OD600 value reached ~1.0. For good
aeration, the medium constituted no more than one-fifth of the total tube volume,
and growth was carried out in a shaking incubator at 225 rpm. Thereafter, the cell
solution was collected in 10 mL conical vial and centrifuged at 3000 x g for 5 min,
followed by wash with 5 mL of cold water and centrifuged again at 3000 x g for 5
min and stored at – 80 ⁰C for mass spectrometry lipidomics studies.
Fluorescence Imaging using Saccharomyces cerevisiae cells using coppercatalyzed click reaction. Two 1 mL samples of S. cerevisiae cells, one treated
with compound 3.1 (study) and one untreated (control), were incubated with 10
µM Azide-Fluor 488 dimethylsulfoxide (DMSO) solution for 1 hr at rt. For this,
first the Azide-Fluor 488 (2.60 µL, 3.828 mM) DMSO solution, copper (II) sulfate
pentahydrate

(4.50

µL,

4.01

mM)

followed

by

Tris(3-

hydroxypropyltriazolylmethyl)amine (13.30 µL, 8.29 mM), sodium ascorbate (3.10
µL, 325 mM) and 976.5 µL mili Q water were added. Next, the cell samples were
centrifuged for 3 min at 2500 rpm, the dye solutions were removed, and the cells
were washed with 20% DMSO in water three times, vortexing and centrifugation
at 2500 rpm for 3 min performed in between each washing step. Next, 1 mL icecold methanol was added to each tube, and after incubating for 10 min at 0 oC,
the sample was centrifuged. Next, 1 mL of Phosphate Buffered Saline solution
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(PBS, pH 7.4, 1.19 mM phosphates) was used to wash the fixed cell samples,
which were then centrifuged at 2500 rpm for 3 min. Cells were then subjected to
fluorescence microscopy.
Lipid extraction and mass spectrometry. This protocol was adapted from that
described by Bligh and Dyer. All operations with extracted lipids were done using
glass pipettes or syringes; plastics will create a large background signal if they
come into contact with chloroform on mass spectra. Frozen cells were
resuspended in 1.6 mL of ice-cold distilled water and transferred to high-speed
glass centrifuge tubes. 6 mL of chloroform and MeOH (1:2) mix and 0.8 ml of
glass beads were added to the cell suspension and vortexed with glass beads
two times for 1 min. Next, 2 ml of chloroform was added and mixed gently, later
incubated for 5 min at room temperature with occasional mixing. 2 ml of distilled
water was added and incubated for 5 min at room temperature with gentle
mixing. The entire liquid phase was collected into a new high-speed glass
centrifuge tube after centrifuging for 5 min at 3000 x g at room temperature. 3.2
mL of chloroform was added to the remaining cell pellets and vortexed two times
for 1 min. The cell pellets were centrifuge for 5 min at 3000 x g at room
temperature and the supernatant was transferred to the liquid phase collected
before. Now, the whole liquid phase (collected from 2 extraction steps) was
centrifuged for 5 min at 3000 x g at room temperature. The upper (aqueous)
phase was discarded and the lower (organic) phase was transferred into a new
high-speed glass centrifuge tube. To remove residual cell pellets, once again the
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organic phase was centrifuged for 5 min at 3000 x g at room temperature. Next,
the entire supernatant was transferred into a glass vial and dried under nitrogen.
The dried lipid film was then dissolved in 150 μL of methanol: chloroform (9:1)
and separated on a Kinetex HILIC column (150 mmx2.1 mm, 2.6 μm)
(Phenomenex, Torrance, CA, USA) connected to an Ultimate 3000 autosampler
and UHPLC pump and an Exactive benchtop Orbitrap mass spectrometer
(Thermo Fisher Scientific, San Jose, CA) equipped with an electrospray
ionization (ESI) probe. Separations were run for 35 min with mobile phase A and
B consisting of 10 mM aqueous ammonium formate pH 3 and 10 mM ammonium
formate pH 3 in 93% (v/v) acetonitrile (ACN) respectively. The gradient started at
100% B for 1 min; and was from 1 to 15 min decreased to 81% B, from 15 to
15.1 min to 48% B, from 15.1 to 25 min maintained at 48% B, from 25 to 25.1
min increased to 100% B, and from 25.1 to 35 min maintained at 100% B. The
column oven temperature was maintained at 25 °C and the temperature of the
auto sampler was set to 4 °C. The same LC conditions and buffers were used for
all MS experiments with a flow rate of 0.2 mL/min. The spray voltage was set to 4
kV and the heated capillary was set at 350 °C. The sheath gas flow was set to 25
units and the auxiliary gas set to 10 units. These conditions were held constant
for both positive and negative ionization mode acquisitions. External mass
calibration was performed using the standard calibration mixture and protocol
from ThermoFisher approximately every 2 days. For full scan profiling
experiments, the MS was run with resolution of 140,000k with a scan range of
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100-1500 m/z. Each sample was run in both positive and negative mode.
Samples were run in positive and negative mode and full scan settings were the
same. For the all ion fragmentation scans, the resolution was 140,000 with a
scan range of 100-1500 m/z. The normalized collision energy was 30eV with
stepped collision energy of 50%. Full scan data was evaluated using Maven
software. Lipid classes were identified by their fragments using Xcalibur software
(Thermo Fisher Scientific, San Jose, CA).

tert-Butyl 3-(tert-butoxy)-2-(prop-2-yn-1-ylamino)propanoate (3.4). O-tertButyl-L-serine tert-butyl ester hydrochloride (3.3, 0.200 g, 0.788 mmol) was
washed with 5% ammonia solution and extracted with 75 mL dichloromethane
(DCM) (3 x 25 mL). The DCM layers were collected in a 250 mL round-bottomed
flask (RBF), the solvent was removed by rotary evaporation, and the sample was
subjected to high vacuum. Next, dry N,N-dimethylformamide (DMF, 200 mL) was
added, followed by anhydrous potassium carbonate (0.239 g, 1.734 mmol) and
the mixture was allowed to stir for 30 min. Next, propargyl bromide (0.947 g,
0.946 mmol,) was added. The reaction was then allowed to stir overnight, after
which ice-cold water (200 mL) was added, and the aqueous portion was
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extracted with dichloromethane (3 x 25 mL). The organic layers were then
combined and dried with magnesium sulfate, filtered and concentrated by rotary
evaporation. Column chromatography using gradient elution with 10-50% ethyl
acetate-hexanes gave 3.4 as yellow oil (72.7 mg, 36% yield). 1H NMR (500 MHz,
CD3OD): δ 3.6 (dd, J = 8.5 hz, 5.0 hz 1H), 3.54 (m, 2H), 3.42 (d, J = 2.5 Hz, 1H),
3.46 (m, 1H), 2.19 (t, J = 2.5 Hz, 1H), 2.06 (broad s, 1H), 1.47 (s, 9H), 1.15 (s,
9H).

13

C NMR (126 MHz, CD3OD): δ 171.80, 81.74, 81.15, 72.93, 71.44, 63.12,

60.65, 36.69, 28.11, 27.37. HRMS-DART [M+H]- calcd for C14H29N4O3+,
256.1907; found 256.1908.

3-Hydroxy-2-(prop-2-yn-1-ylammonium)propanoic

acid

trifluoroacetate

(3.1). Protected alkynyl-serine 3.4 (25.0 mg, 0.098 mmol) was dissolved in DCM
(1 mL), treated with trifluoroacetic acid (TFA, 4 mL), and the solution was allowed
to stir for 8 h. The excess TFA was then removed by co-evaporation with DCM
and the crude was placed on the high vacuum for overnight. The product 3.1 was
purified by reverse phase column chromatography and obtained as a transparent
solid (21.4 mg, 85% yield). 1H NMR (500 MHz, CD3OD): δ 3.91 (dd, J = 4.1 hz,
107

2.2 Hz, 2H), 3.90 (dd, J = 2.5 Hz, 1.3 Hz, 2H), 3.84 (t, J = 4.1 Hz, 1H), 2.87 (t, J =
2.6 hz, 1H).

13

C NMR (126 MHz, CD3OD): δ 170.78, 78.06, 73.00, 62.04, 59.02,

35.33. HRMS-DART [M+H]- calcd for C6H10NO3+, 144.0655; found 144.0655.
1-Azido-3-bromopropane. 1,3-dibromopropane (0.400 g, 1.98 mmol) was
transferred to a 250 mL RBF in DMF and refluxed with sodium azide (0.155 g,
2.377 mmol) at 55 oC overnight. Next, ice cold water (200 mL) was added and
the crude was extracted with DCM (3 x 25 mL). The remaining water was
adsorbed on anhydrous magnesium sulfate and the solvent was removed by
rotary evaporation to yield light yellow oil (276 mg). The mass spectrum showed
that conversion of bromide to azide group was completed, and the crude was
passed on without any purification.

tert-Butyl 2-((3-azidopropyl)ammonium)-3-(tert-butoxy)propanoate chloride
(3.5). O-tert-Butyl-L-serine tert-butyl ester hydrochloride (3.3, 0.200 g, 0.788
mmol) was washed with 5% ammonia solution and extracted with DCM (3 x 25
mL). The DCM layers were combined in a 250 mL RBF, the solvent was removed
by rotary evaporation, and the contents were place under high vacuum. Next,
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200 mL of dry DMF was added, followed by anhydrous potassium carbonate
(0.239 g, 1.734 mmol), and the mixture was allowed to stir for 30 min. Next, 1azido-3-bromopropane (0.155 g, 0.946 mmol) was added. The reaction was then
allowed to stir overnight at 54 0C, after which ice-cold water (200 mL) was
added, and the aqueous portion was extracted with DCM (3 x 25 mL). The
organic layers were then combined and dried with magnesium sulfate, filtered
and concentrated by rotary evaporation. Column chromatography using gradient
elution with 10-50% ethyl acetate-hexanes gave 3.5 as yellow oil (82.8 mg, 35%
yield). 1H NMR (500 MHz, CD3OD): δ 5.50 (d, J = 8.5 Hz, 1H), 4.32 (d, J = 8.9
Hz, 1H), 4.15 (m, 2H), 3.78 (m, 1H), 3.53 (d, J = 11.3 Hz, 2H), 3.38 (dd, J = 15.2
Hz, 6.8 Hz, 2H), 1.9 (dq, J = 12.9 Hz, 6.5 Hz, 2H), 1.47 (s, 9H), 1.15 (s, 9h).

13

C

NMR (126 MHz, CD3OD): δ 169.57, 81.78, 73.05, 62.25, 61.83, 54.84, 48.17,
28.56, 28.00, 27.30. HRMS-DART [M-H]- calcd for C14H29N4O3+, 301.2240; found
301.2237.

2-((3-azidopropyl)ammonium)-3-hydroxypropanoic

acid

chloride

(3.2).

Protected azido-serine 3.5 (25.0 mg, 0.083 mmol) was dissolved in 1,4-dioxane
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(1.5 mL) and treated with hydrochloric acid (3.5 mL, 8 M), and the mixture was
allowed to stir for 8h at 70 oC. After that, the solvent was removed by rotary
evaporation, and a reverse phase C18 column provided 3.2 (14.3 mg, 91% yield)
as a light yellowish liquid. 1H NMR (500 MHz, CD3OD): δ 4.71 (m, 1H), 4.33 (m,
2H), 4.03 (m, 2H), 3.52 (q, J = 6 Hz, 1H), 2.13 (m, 2H).

13

C NMR (126 MHz,

CD3OD): δ 169.68, 81.77, 54.86, 29.17, 28.04, 27.33. HRMS-DART [M+H]- calcd
for C6H11N2O2+, 143.082; found 143.082.

(2S)-2-((tert-butoxycarbonyl)amino)-3-((tetrahydro-2H-pyran-2yl)oxy)propanoic acid (3.10). N-(tert-Butoxycarbonyl)-L-serine (3.9, 0.500 g,
2.44 mmol) was transferred to a 250 mL round-bottomed flask and added
pyridinium p-toluene sulfonate (0.736 g, 2.92 mmol) and dihydropyran (0.267 g,
2.92 mmol) in 150 mL DCM. The reaction mixture is stirred for overnight and
extracted with DCM (3 x 25 mL). The DCM layers were collected in a 250 mL
round-bottomed flask (RBF) and the solvent was dried with magnesium sulfate,
filtered and removed by rotary evaporation. Column chromatography using
gradient elution with 10-50% ethyl acetate-hexanes gave 3.10 as white solid
(0.663 mg). It was used in the next step without characterization.
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tert-butyl

((2S)-1-oxo-1-(prop-2-yn-1-ylamino)-3-((tetrahydro-2H-pyran-2-

yl)oxy)propan-2-yl)carbamate (3.11): To a 250 mL round-bottomed flask, 3.10
(0.325 g, 1.12 mmol) was taken with hydroxybenzotriazole (HOBt, 0.151 g, 1.12
mmol)

and

O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium

hexafluorophosphate (HBTU, 0.425 g, 1.12 mmol) and DIEA (0.434 g, 3.36
mmol). After stirring for 15 min, propargylamine ( 0.74 g, 1.347 mmol) was added
to the reaction mixture which was allowed to react for overnight. After reaction
completion, the reactionmixture was extracted with DCM (3 x 25 mL). The DCM
layers were collected in a 250 mL round-bottomed flask (RBF), the solvent was
dried with magnesium sulfate, filtered and removed by rotary evaporation.
Column chromatography using gradient elution with 10-50% ethyl acetatehexanes gave 3.11 as yellow oil (0.139 mg).
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(S)-3-hydroxy-1-oxo-1-(prop-2-yn-1-ylamino)propan-2-ammonium

2,2,2-

trifluoroacetate (3.8). Compound 3.11 (0.100 g, 0.306 mmol) was dissolved in
DCM (5 mL) and TFA (5 mL) and stirred overnight. The excess TFA was
evaporated off using rotary evaporation, and a reverse phase C18 column (5%
methanol in water) provided 3.8 (60.1 mg, 77% yield) as a light yellowish liquid.
1

H NMR (500 MHz, CD3OD): δ 4.07 (d, J = 2.6 Hz, 1H), 3.99 (d, J = 2.6 Hz, 1H),

3.93 (m, 2H), 3.82 (dd, J = 11.2, 5.8 Hz, 1H), 2.62 (t, J = 2.6 Hz, 1H).

13

C NMR

(126 MHz, CD3OD): δ 170.01, 155.43, 99.45, 80.07, 79.34, 71.45, 67.64, 62.60.
HRMS-DART [M-H]- calcd for C6H11N2O2+, 143.082; found 14.082.

(S)-3-((11-bromoundecyl)oxy)propane-1,2-diol (3.15). S-glycidol (3.17), 0.500
g, 6.75 mmol) in DCM (250 mL) was transferred to a 500 mL round-bottomed
flask and boron trifluordie diethyl etherate (0.96 g, 0.675 mmol) was added to it,
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stirred for 15 min. Next, 1-bromoundecanol 3.18 (1.8 g, 7.166 mmol) was added.
The reaction mixture is stirred for overnight and extracted with DCM (3 x 50 mL).
The DCM layers were collected in a 250 mL round-bottomed flask (RBF), the
solvent was dried with magnesium sulfate, filtered and removed by rotary
evaporation. Column chromatography using gradient elution with 10-40% ethyl
acetate-hexanes gave 3.15 as white solid (0.615 mg). It was used in the next
step without characterization.

(S)-3-((11-azidoundecyl)oxy)propane-1,2-diol (3.16). To a 250 mL roundbottomed flask, 3.15 (0.400 g, 1.229 mmol) transferred in DMF and sodium azide
(0.199 g, 3.074 mmol) were added and refluxed at 55 oC overnight. Next, ice cold
water (200 mL) was added and the crude was extracted with DCM (3 x 25 mL).
The remaining water was adsorbed on anhydrous magnesium sulfate and the
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solvent was removed by rotary evaporation to yield light yellow oil (295 mg). The
the crude was passed on without any purification.

(R)-3-((11-azidoundecyl)oxy)-2-hydroxypropyl diethyl phosphate (3.20). To a
50 mL round-bottomed flask containing 5 mL dry DCM was added 3.19 (0.016 g,
0.090 mmol) and 2,2,6,6-Tetramethylpiperidine(TMP) (0.0127 g, 0.090 mmol)
and stirred at 0 oC for 15 min. Then, 3.16 (0.020g, 0.070 mmol) was added and
stirred for overnight. Resulting reaction mixture was treated with aquesous
solution and extracted with DCM (3 x 15 mL). Later, DCM layer was dried over
magneisum sulfate, filtered and DCM layer was evaporated off using a rotary
evaporation. Column chromatography using gradient elution with 25%-100%
ethyl acetate-hexanes gave 3.20 as white solid (0.021 g).
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(R)-3-((11-azidoundecyl)oxy)-2-hydroxypropyl dihydrogen phosphate (3.21).
In a 25 mL round-botomed flask, added 3.20 (0.020 g, 0.0472 mmol) and
trimethylsilylbromide (TMSBr) (0.145 g, 0.944 mmol) in 2 mL dry DCM. The
reaction mixture was allowed to stir for 10-12h, after that the DCM layer was
evaporated off and dry methanol was added and stirred for 2h. The resulting
mixture was again subjected to rotary evaporation and a reverse phase C18
(10% methanol in water) column provided 3.21 (60.1 mg, 77% yield) as a light
yellowish liquid. 1H NMR (500 MHz, CD3OD): δ 3.66 (m, 1H), 3.54 (m, 2H), 3.34
(m, 2H), 3.27 (t, J= 2.56 Hz, 1H), 1.60 (m, 4H), 1.27 (s, 16H).

13

C NMR (75 MHz,

CDCl3): δ 71.82, 70.41, 64.45, 63.04, 32.77, 29.38, 27.18, 25.70.

31

P NMR (75

MHz, D2O) δ 0.21. HRMS-DART [M-H]- calcd for C14H31N3O6P+, 368.1943; found
368.2542.
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3.14 List of Spectra

Spectra 3.1: 1H NMR and 13C NMR of compound 3.4. tert-Butyl 3-(tertbutoxy)-2-(prop-2-yn-1-ylamino)propanoate.
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Spectrum 3.2: Mass Spectrum of compound 3.4. tert-Butyl 3-(tert-butoxy)-2(prop-2-yn-1-ylamino)propanoate.
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D 2O
Spectra 3.3: 1H NMR and 13C NMR of compound 3.1. 3-Hydroxy-2-(prop-2yn-1-ylammonium)propanoic acid trifluoroacetate.
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Spectrum 3.4: Mass Spectrum of compound 3.1. 3-Hydroxy-2-(prop-2-yn-1ylammonium)propanoic acid trifluoroacetate.

119

Spectra 3.5: 1H NMR and 13C NMR of compound 3.5.
tert-butyl-(3-azidopropyl)-O-(tert-butyl)-L-serinate.
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.

Spectrum 3.6: Mass Spectrum of compound 3.5. tert-butyl N-(3azidopropyl)-O-(tert-butyl)-L-serinate.
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Spectra 3.7: 1H NMR and 13C NMR of compound 3.2. 2-((3azidopropyl)ammonium)-3-hydroxypropanoic acid chloride.
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Spectrum 3.8: Mass Spectrum of compound 3.2. 2-((3azidopropyl)ammonium)-3-hydroxypropanoic acid chloride
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Spectra 3.9: 1H NMR and 13C NMR of compound 3.8. (S)-3-hydroxy-1-oxo-1(prop-2-yn-1-ylamino)propan-2-ammonium 2,2,2-trifluoroacetate.
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Spectrum 4.0: Mass spectrum of compound 3.8. (S)-3-hydroxy-1-oxo-1(prop-2-yn-1-ylamino)propan-2-ammonium 2,2,2-trifluoroacetate.
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Spectra 4.1: 1H NMR and 13C NMR of compound 3.21. (R)-3-((11azidoundecyl)oxy)-2-hydroxypropyl dihydrogen phosphate.
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Spectra 4.2: Mass and 31P spectra of compound 3.21. (R)-3-((11azidoundecyl)oxy)-2-hydroxypropyl dihydrogen phosphate.
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Table 3.1: List of alkyne labeled phospholipids detected on mass
spectrophotometer.
Name

Formula

Lab
LysoPS 2 C25H44NO9P
Lab
LysoPS 3 C27H48NO9P
Lab PC10 C42H80NO8P
Lab PC5 C40H72NO8P
Lab PC7 C40H76NO8P
Lab PS3 C41H74NO10P
Lab PS5 C43H76NO10P
Lab PS6 C43H78NO10P
Lab PS7 C45H80NO10P

Predicat Observ Error RT No. of Predict %
ed m/z ed m/z (ppm)
Carbo ed % 13C
n
13C peak
peak
23.1
532.270 532.266 7.14 12
25
27.50
7
27.4
560.300 560.298 4.46 12
27
29.70
1
45.4
758.559 758.569 12.52 11
42
46.20
6
42.0
726.507 726.507 0.41 9
40
44.00
5
44.8
730.528 730.535 9.46 9
40
44.00
3
38.4
770.498 770.497 1.82 9
41
45.10
8
41.9
796.513 796.513 0.38 9
43
47.30
3
44.0
798.529 798.529 0.09 10
43
47.30
8
31.2
824.545 824.545 0.49 10
45
49.50
2
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Table 3.2: List of azide labeled phospholipids detected on mass
spectrophotometer.
Name

Lab PS6
Lab PS4N2
Lab PS3
Lab PS1Na
Lab PC12Na
Lab PC2
Lab
MMPE9Na
Lab
MMPE2
Lab
LysoPS1
Lab
DMPE8Na

Formula

C43H82N4O
10P
C41H79N2O
10P
C41H78N4O
10P
C37H69N4N
aO10P
C44H85N4N
aO8P
C36H72N4O
8P

Predicat Observed Error
ed m/z
m/z
(ppm
)

RT

790.547

16.9
845.562
0
14.2
790.558
8

817.545

817.538 8.23

16

783.464

783.456 9.75

13

851.600

851.594 7.27

8

719.508

719.509 1.52

13

845.576

C42H81N4N
aO8P
823.568
C36H72N4O
8P
719.508
C25H50N4O
9P
581.331
C43H83N4N
aO8P
837.584

18
14

No. Predicte %
of d % 13C 13C
Carb peak peak
on
37.3
43
47.30
6
39.6
41
45.10
2
42.5
41
45.10
6
35.7
37
40.70
9
44.5
44
48.40
0
33.1
36
39.60
4

823.561 8.90

8

42

46.20

719.509 1.52

14

36

39.60

581.330 1.38

12

25

27.50

55.3
8
33.1
4
23.4
9

837.576 9.27

8

43

47.30

66.3
7

129

3.15: List of Chromatogram and Mass Spectra of N-Alkynyl Labeled
Phospholipids
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3.16 List of Chromatogram and Mass Spectra of N-Propylazido Labeled
Phospholipids
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CHAPTER FOUR
SYNTHESIS OF POTENTIAL PHOSPHATIDYLSERINE SYNTHASE
(PS) INHIBITORS
4.1 Detrimental Effect of Candida Species
Only a relatively small number of Candida species are pathogenic for humans
and

can

cause

serious

infections

in

a

suitable

environment

or

an

immunocompromised body system where the immune system in the host is
damaged.150 Organisms capable of triggering a variety of superficial and deepseated mycoses generally exist in the gastrointestinal and genitourinary tracts as
well as the exteriors of mucosa tissues. Moreover, Candida species (spp.) have
the unique ability to form biofilms, a uniform framework of microorganism on the
adhering surface.151 Biofilms grown by Candida spp. on implanted medical
devices are recognized as one of the primary source for spreading infections. 152
Mortality rates are extensively high (~40%) for device-associated Candida spp.
infections and US$2.6 billion is the annual expenditure on antifungal therapies in
the United States alone.153-155 Every year, about 10 million people are under
threat of receiving these implant related infections when they are exposed to
different medical devices such as venous catheters, urinary catheters, prosthetic
heart valves and artificial joints as a result of adherent microbial colonies on the
surfaces of these devices.156 Microbial communities typically grow on the most
widely

used

surgically

implanted

devices.

Furthermore,

these

medical

apparatuses can malfunction due to the biofilm developed inside, resulting in
149

defective valve mechanisms. Importantly, Candida spp. biofilms are less
susceptible to a number of antimicrobial agents and thus lead to more intricate
treatment of the infected patients requiring surgical removal of the biofilms and
replacement of the infected devices.157, 158
There are limited classes of antifungal drugs that can inhibit the production of
the fungi and hence there is a crucial need to develop new remedies.
Remarkably, in the past two decades, researchers have only developed one new
class of antifungal agents.159 The few antifungals that are available can be
categorized into three main classes to C. albicans bloodstream infections: azoles
(fluconazole, itraconazole) and polyenes (amphotericin B) and echinocandins
(caspofungin). These drugs mainly target the fungal sterol ergosterol 160, thereby
damaging the fungal cell wall161, 162. Unfortunately, they exhibit poor efficacy due
to drug resistance (azoles), high toxicity (amphotericin B) and rare oral
availability (polyenes, echinocandins).

160, 163, 164

Thus the investigation and

exploration of effective treatments and new antifungal drugs need serious
attention

165

. The fungal PS synthase, Cho1p, represents a promising new drug

target, which was revealed by the lab of our collaborator, Dr. Todd Reynolds in
the University of Tennessee, Department of Microbiology. The reason for this is
that, the fungal Cho1p enzyme catalyzes the conversion of cytidyldiphosphate
diacylglycerol (CDP-DAG) in the presence of serine into PS as well as the
byproduct cytidylmonophosphate (CMP)146, 166. The key is that this transformation
occurs in Candida species, but not in mammals, which instead use two PS
150

synthase enzymes, Pss1p and Pss2p, to exchange head groups from PC or PE,
respectively, through reaction with serine to produce PS

166,

167

. Since

mammalian and fungal systems follow two different biosynthetic routes for
production of PS, an inhibitor of Cho1p could be very specific for fungi but
ineffective against the mammalian PS synthases, Pss1p and Pss2p. (Figure
4.1). This also depicts that PS is produced only through the de novo pathway in
the case of fungal cells whereas PE and PC can be made via both Kennedy and
de novo pathways168 in mammals.
For this reason, we set out to develop inhibitors of the PS synthase Cho1p as
a first step towards a therapeutic treatment and/or biological tool for this enzyme.
Here, preliminary studies with our clickable serine analogs described in Chapter
3 suggested that modified versions of serine may effectively inhibit this enzyme.
Additionally, it is noteworthy that Bahtiar et al., demonstrated O-t-Butyl-L-serine
methyl ester hydrochloride (H-Ser(tBu)-OMe-HCl) as a promising as an inhibitor
of

osteoclatogenesis,

perhaps

by

inhibiting

sphingolipid

biosynthesis. 169

Therefore, L-serine analogs may emerge as effective PS synthase inhibitors that
can be used for antifungal therapy.
4.2 Determination of PS Synthase Activity
To measure the PS synthase activity directly in vitro, our collaborator Dr.
Todd Reynolds lab has developed a PS synthase assay170,
exploited PS synthase inhibition.
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that can be

Figure 4.1: Different routes for production of PS in mammalian and yeast
cells. Two well-known pathways used by yeast and mammalian cells to
produce phospholipids. 1) The de novo pathway is different whereas the
Kennedy pathway is similar for two kinds of organisms. Fungi use Cho 1p
PS synthase to synthesize PS from serine (Ser) and CDP-DAG, whereas
mammals use Pss1p and Pss2p to synthesize PS from serine and PC or PE
respectively.
Quantification and
comparison of
radiolabeled PS in
both achieved by
scintillation
counter

Scheme 4.1: Principle of PS synthase assay for measurement of inhibition
activity of serine analogs.
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In this assay, [3H]-L-serine is reacted with CDP-DAG in the presence of a
Candida membrane extract containing Cho1p (Scheme 4.1). The lipid products
are then separated by thin layer chromatography (TLC), and scintillation counting
is used to detect the abundance of [3H]-labeled PS products. To exploit this
assay to evaluate inhibition, this is run in the presence (study) and absence
(control) of prospective inhibitors at varying concentrations. Thus, competition
with [3H]-L-serine with varying concentrations of serine analogs will determine
their ability to inhibit the production of [3H]-PS. Here, wild type (WT) and cho1∆∆
(C. albicans with Cho1 knocked out) strains are employed as positives control for
complete inhibition of PS synthesis. After incubation at 37 °C for a specific time
(5-10 min), the unincorporated [3H]-L-serine is washed away and only the
chloroform soluble lipid product, PS is collected. After drying overnight, PS with
incorporated [3H]-L-serine is counted via a scintillation counter to determine
enzyme activity. Compounds that decrease the production of [3H]-PS will be
further tested by using them as competitors for deuterium labeled serine in
membranes.
4.3 Synthesis of L-Serine Analogs
We designed L-serine analogs (Scheme 4.2) with modifications at either the
amine or hydroxyl groups of serine. For modification of the hydroxyl group, this
group was converted into an ether when attaching new functionality. For
alteration of the amine group, we studied the clickable serine analogs described
in and added other groups to the nitrogen through alkylation as well. Our
153

synthesis started with L-serine methyl ester hydrochloride (4.6) which was
treated with boc anhydride in the presence of triethylamine to protect the amino
group (Scheme 4.3). Next, the hydroxyl methylation was carried out using methyl
iodide and sodium hydride. Finally, the boc group and the methyl ester group
were deprotected using TFA in DCM to obtain compound 4.1. To synthesize
compounds 4.2, 4.3 and 4.4, a general protocol was followed. In the first step,
compound 3.3 was treated with alkyl halide in presence of potassium carbonate
in DMF to obtain the desired intermediate (Scheme 4.4). These were then
deprotected using either hydrochloric acid in dioxane-DCM or TFA-DCM mixture.
The reason for switching from TFA to HCl is discussed in the next section.

Figure 4.2: L-serine analogs synthesized for PS synthase assay.
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Scheme 4.3: Synthesis of serine analogs with modification of hydroxyl
group.

Scheme 4.4: Synthesis of serine analogs with modification of amino group.

4.4 PS Synthase Assay Results
A number of compounds have been synthesized by our lab of which a few
were already described labeling of phospholipids in the previous chapter. Many
of these analogs have been assessed for PS inhibition by Chelsi Danielle
Cassilly in Dr. Todd Reynolds lab in the Microbiology Department of the
University of Tennessee. The compound we first studied for PS synthase
inhibition was 4.1, which is an O-methoxy serine analog, and it showed very low
inhibition activity (Figure 4.3). At 25 mM concentration, the analog 4.1 only
reduced the activity by ~20%.
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Figure 4.3: L-serine analogs assessed through a PS synthase assay
demonstrating decreased [3H]- PS s in the presence of an effective
inhibitor.
156

Next, compound 3.1 showed a promising indication as an inhibitor when 25
mM of this compound was treated with protein in the presence of natural 3H
labeled serine. While this concentration is too high for this analog to act as a
suitable drug candidate for candida associated diseases, it does provide some
activity that could be optimized through further probe modification. Similar results
were observed for compound 4.2, which is a product of mono-methylation of
serine at the amine. This exhibited pronounced inhibition activity at 25 mM as
well. We also wanted to see the effect of alkylation degree on inhibition of PS
synthase assay. For this purpose, we synthesized the trialkyl substituted serine
analog 4.3, and this compound showed similar results to 4.3 at 25 mM.
Interestingly, at 5 mM it showed a slight decrease (less than 10%) in PS
production.
After obtaining reduced production of radiolabeled PS with these N-alkylated
serine analogs, we decided to explore additional compounds in which the amine
position was modified. Next, N-benzyl serine analog 4.4 was evaluated through
the PS synthase assay, which exhibited significant inhibition of PS synthase at
25 mM concentration (Figure 4.3A). The PS production was reduced by almost
90% of the original value of PS produced in untreated sample. Moreover, for the
first time, we noticed that 5 mM of 4.4 showed a significant decrease in PS
production, leading to an almost 50 % decrease in PS production. However,
when the same assay was repeated (Figure 4.3B), inhibition was not as
significant since 5 mM of compound 4.4 reduced PS production by only, which
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was unexpected since the first assay provided satisfactory results. We have
remade and retested this compound multiple times and the results have been
variable. One reasons for this might be the trifluoroacetate salt of serine we
employed in the assay, which could cause problems such as protein precipitation
and may thus yield misleading results. Next, we attempted compound 4.5
containing an azido-propyl chain attached to the amine. Figure 4.4 shows that
the PS assay was run three times with this compound and every time we
observed pronounced inhibition of PS synthase at 5 mM concentration. To test
the counter-ion effect of the salt of compound 4.5, we used hydrochloric acid in
place of trifluoroacetic acid in the final deprotection to synthesize 3.2 and
evaluated this compound using the PS synthase assay. The reason behind
changing the counter-ion is that trifluoroacetate can cause precipitation of
proteins resulting in nonfunctional protein in solution leading to ambiguous
results, whereas chloride ion does not have such an effect on proteins. Figure
4.4A depicts that the first trial yielded significant inhibition of PS synthase at only
500 micromolar concentration of 3.2, which was the best result thus far
(~60%.reduced activity). Unexpectedly, we didn’t see the same inhibition activity
when we ran a second trial with a new batch of 3.2 (Figure 4.4B).
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Figure 4.4: PS synthase assay results with compounds 3.2 and 4.5.
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4.5 Conclusion
The investigation for active compounds towards PS synthase inhibition is still
in progress. So far, we have synthesized a number of serine analogs and
showed the simple modification at different positions of the amino acid may lead
to inhibition. Our group is working on making cysteine analogs, which recently
showed better results than serine analogs for PS synthase inhibition. Recent, PS
synthase assay result showed that our cysteine analogs compete with natural
cysteine in PS assay. Tanei Ricks from our lab currently is synthesizing a
number of cysteine analogs at the amine and thiol groups.to show better
inhibition of PS synthase.
4.6 Experimental
Reagents and solvents were generally purchased from Acros, Aldrich or
Fisher Scientific and used as received. L-serine methyl ester hydrochloride was
purchased from Fisher Scientific. CDP-DAG and 3H serine were obtained from
Avanti Polar Lipids and American Radiolabeled Chemicals respectively. SiliaPrep
C18 (17%, 2g, 6mL, 40-63um) was obtained from SiliCycle Inc. Dry solvents
were obtained from a Pure solvent delivery system purchased from Innovative
Technology, Inc. Column chromatography was performed using 230-400 mesh
silica gel purchased from Sorbent Technologies. NMR spectra were obtained
using Varian Mercury 500 and 600 spectrometers. Mass spectra were obtained
with JEOL DART-AccuTOF mass spectrometer with high-resolution capabilities
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spectrometer. The scintillation counter is a Packard TriCarb 2900TR Liquid
Scintillation Counter used for quantification of radio labeled PS.

(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-hydroxypropanoate (4.7). To a
100 mL round bottomed flask, was added L-serine methylester hydrochloride
(4.6) (0.120 g, 0.771 mmol), trimethylamine (Et3N) (0.172 g, 1.7 mmol) and boc
anhydride (0.168 g, 0.771 mmol) in 20 mL dry tetrahydrofuran (THF). The
reaction mixture was allowed to stir for overnight. After rotary evaporation of
THF, 50 mL of water was added and the aqueous layer was extracted with DCM
(3 x 25 mL). The organic layers were then combined and dried with magnesium
sulfate, filtered and concentrated by rotary evaporation. The compound 4.7 was
passed on to next step without purification.
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(S)-methyl

2-((tert-butoxycarbonyl)amino)-3-methoxypropanoate

(4.8).

Compound 4.7 (0.100 g, 0.369 mmol) was transferred to a 50 mL round
bottomed flask in 10 mL of dry DMF and sodium hydride (0.035 g, 1.476 mmol)
was added at 0 ⁰C under a nitrogen atmosphere. After 30 min of stirring, methyl
iodide (0.525 g, 1.6 mmol) was added to the reaction mixture and the reaction
was stirred overnight. Next, 25 mL of water was added and the aqueous solution
was extracted with DCM (3 x 25 mL). The organic layers were then combined
and dried with magnesium sulfate, filtered and concentrated by rotary
evaporation. The compound was passed on to next step without purification.

(S)-1-carboxy-2-methoxyethanammonium

2,2,2-trifluoroacetate

(4.1).

Compound 4.8 (25.0 mg, 0.108 mmol) was dissolved in DCM (1.5 mL) and
treated with trifluoroacetic acid (5.0 mL), and the mixture was allowed to stir for
8h. After that, the solvent was removed by rotary evaporation, and a reverse
phase C18 column with 5% methanol in water provided 4.1 (10.15 mg, 81%
yield) as a white solid. 1H NMR (500 MHz, CD3OD): δ 3.89 (m, 1H), 3.81 (t, J =
4.1 Hz, 1H), 3.36 (m, 1H), 2.75 (s, 3H). HRMS-DART [M+H]- calcd for
C4H10NO3+, 120.0655; found 120.0684.
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tert-butyl O-(tert-butyl)-N-methyl-L-serinate (4.9). O-tert-Butyl-L-serine tertbutyl ester hydrochloride (3.3, 0.200 g, 0.788 mmol) was washed with 5%
ammonia solution and extracted with DCM (3 x 25 mL). The DCM layers were
combined in a 250 mL RBF, the solvent was removed by rotary evaporation, and
the contents were place under high vacuum. Next, 200 mL of dry DMF was
added, followed by anhydrous potassium carbonate (0.239 g, 1.734 mmol), and
the mixture was allowed to stir for 30 min. Next, iodomethane (0.134 g, 0.935
mmol) was added. The reaction was then allowed to stir overnight, after which
ice-cold water (200 mL) was added, and the aqueous portion was extracted with
DCM (3 x 25 mL). The organic layers were then combined and dried with
magnesium sulfate, filtered and concentrated by rotary evaporation. The
compound was passed on to next step without any purification.
The same reaction procedure was followed for making compound 4.10 and
4.11. For synthesizing 4.10, iodomethane (0.415 g, 2.81 mmol) was treated with
0.200 g (0.788 mmol) of 3.3 whereas 0.178 g (0.788 mmol) benzyl bromide was
reacted with 0.200 g (0.788 mmol) of 3.3 to obtain 4.11.
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(S)-1-carboxy-2-hydroxy-

N-methylethanammonium

2,2,2-trifluoroacetate

(4.2). Compound 4.9 (25.0 mg, 0.108 mmol) was dissolved in DCM (1.5 mL) and
treated with trifluoroacetic acid (5.0 mL), and the mixture was allowed to stir for
8h. After that, the solvent was removed by rotary evaporation, and a reverse
phase C18 column with 5% methanol in water provided 4.2 (22.40 mg, 89%
yield) as a light yellowish liquid. 1H NMR (500 MHz, CD3OD): δ 4.20 (m, 1H),
3.78 (m, 2H), 3.55 (s, 3H). HRMS-DART [M+H]- calcd for C4H10NO3+, 120.0655;
found 120.1002.

(S)-1-carboxy-2-hydroxy-N,N,N-trimethylethanammonium

2,2,2-

trifluoroacetate (4.3). To a solution of 4.10 (0.025 g, 0.096 mmol) in 1.5 mL
DCM, added 5.0 mL of trifluoroacetic acid and stirred for couple of hours. A white
product for 4.3 was obtained after reverse phase column with 10% methanol in
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water employed 19.53 mg (92% yield). 1H NMR (300 MHz, D2O): δ 4.06 ((d, J =
4.4 Hz, 3H)), 3.93 (t, J = 4.6 Hz, 1H), 3.14 (s, 9H). HRMS-DART [M+H]- calcd for
C6H14NO3+, 148.0973; found 147.1124.

(S)-N-benzyl-1-carboxy-2-hydroxyethanammonium

2,2,2-trifluoroacetate

(4.4). To a solution of 4.11 (0.025 g, 0.0813 mmol) in 1.5 mL DCM, was added
5.0 mL of trifluoroacetic acid and the reaction stirred for 9h. A reverse phase
column with 10% methanol in water employed compound 4.4 as colorless solid
(23.88 mg, 95% yield). 1H NMR (300 MHz, D2O): δ 7.52-7.45 (m, 5H)), 4.30 (s,
2H), 4.02 (m, 2H), 3.88 (m, 2H).

13

C NMR (126 MHz, CD3OD): δ 170.76, 154.89,

130.42, 129.94, 129.67, 129.20, 62.05, 60.85, 59.02, 49.94. HRMS-DART [M+H]calcd for C10H14NO3+, 196.097; found 196.097.
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(S)-3-azido-N-(1-carboxy-2-hydroxyethyl)propan-1-ammonium

chloride

(4.5). Protected azido-serine 3.5 (25.0 mg, 0.083 mmol) was dissolved in DCM
(1.5 mL) and treated with trifluoroacetic acid (3.5 mL, 8 M), and the mixture was
allowed to stir for 8h. After that, the solvent was removed by rotary evaporation,
and a reverse phase C18 column with 10% methanol in water provided 4.5. All
the peaks for 4.5 matched with that of compound 3.2.
Phosphatidylserine Synthase Assay
This procedure was done as described in literature172 with minor alterations.
Wild type cho1ΔΔ candida albicans cultures were grown over night and then
diluted into 1 L YPD, approximately 0.1 OD600/mL. These cultures were shaken
at 30 °C for 6 to 10h. Cells were then harvested by centrifugation at 6,000 x g for
20 minutes. Pellets were then transferred to 50 mL conical tubes and washed
with water and re-pelleted. Supernatant was removed and the wet weight of the
samples was taken. Cell pellets were stored overnight in -80 °C. The following
day, a cold mixture of 0.1 M Tris-Cl pH 7.5, 5 mM β-mercaptoethanol (BME),
10% glycerol, and protease inhibitors (phenylmethylsuphonylfluoride (PMSF),
leupeptin, and pepstatin) was added to the frozen pellets (1mL/g [wet weight])
and allowed to thaw on ice. Cells were lysed using a French Press (three passes
at approximately 13,000 lb/in2). The homogenate was centrifuged at 4 °C for 5
minutes at 3,000 rpm to clear unbroken cells and heavy material. Supernatant
was then spun again at 27,000 g for 10 minutes at 4 °C. For some experiments,
the resulting supernatant was then spun at 100,000 g to collect the lower density
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membranes. Pellets were resuspended in 500 μL to 1 mL of 0.1 M Tris-Cl pH 7.5,
5 mM β-mercaptoethanol (BME), 10% glycerol, and protease inhibitors. This
mixture was aliquoted into microcentrifuge tubes and homogenized to break
apart clumps, keeping on ice as much as possible. Total crude protein
concentration was determined using a Bradford Assay. The optimal assay
mixture contained 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.5 mM MnCl2, 0.1
mM CDP-DAG (Avanti Polar Lipids, Alabaster, AL) added as a suspension in 1%
to 20% Triton X-100, and 0.4 to 0.5 mg protein in a total volume of 0.1 mL. The
PS synthase assay was performed by monitoring the incorporation of 0.5 mM lserine spiked with 5% by volume [3H]-l-serine (~20 Ci/mmol) into the chloroformsoluble product at 37 °C for a predetermined amount of time. The reaction was
terminated by the addition of 1 mL chloroform: methanol (2:1). Following a lowspeed spin, 800 to 1000 μL of the supernatant was removed to a fresh tube and
washed with 200 μL 0.9% NaCl. Following a second low-speed spin, 400 to 500
μL of the chloroform phase was removed to a new tube and washed with 500 μL
of chloroform: methanol: 0.9% NaCl (3:48:47). Following a third low-speed spin,
200 to 300 μL was transferred into scintillation vials (Thermo Fisher Scientific,
San Jose, CA). Tubes were left open in the hood until dried fully. The next day,
2.5 mL scintillation fluid was added to each tube and run through the scintillation
counter.
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4.6.1 List of Spectra

Spectra 4.1: 1H NMR and mass spectra of compound 4.1. (S)-1-carboxy-2methoxyethanammonium 2,2,2-trifluoroacetate.
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Spectra 4.2: 1H NMR and mass spectra of compound 4.2. (S)-1-carboxy-2hydroxy- N-methylethanammonium 2,2,2-trifluoroacetate (4.2).
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Spectra 4.3: 1H NMR and mass spectra of compound 4.3. (S)-1-carboxy-2hydroxy-N,N,N-trimethylethanammonium 2,2,2-trifluoroacetate (4.3).
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Spectra 4.4: 1H and

13

C NMR of compound 4.4. (S)-N-benzyl-1-carboxy-2-

hydroxyethanammonium 2,2,2-trifluoroacetate (4.4).
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Spectrum 4.5: Mass spectra of compound 4.4. (S)-N-benzyl-1-carboxy-2hydroxyethanammonium 2,2,2-trifluoroacetate (4.4).
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